APPLICATION NUMBER:

208464Orig1s000

OTHER REVIEW(S)
This template should be completed by the PMR/PMC Development Coordinator and included for **each** PMR/PMC in the Action Package.

<table>
<thead>
<tr>
<th>NDA/BLA #</th>
<th>208464/Original Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>VEMLIDY® (tenofovir alafenamide), 25 mg tablet</td>
</tr>
<tr>
<td>PMR Description</td>
<td>Conduct the deferred pediatric study to assess the pharmacokinetics, safety/tolerability, and antiviral activity of tenofovir alafenamide in HBV infected subjects 12 to less than 18 years of age, followed by a rollover to a long-term, open-label, extension to assess longer-term pediatric safety and antiviral activity.</td>
</tr>
</tbody>
</table>

PMR Schedule Milestones:
- Final Protocol Submission: March 2016 (submitted)
- Study/Trial Completion: June 2019
- Final Report Submission: December 2019
- Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

   - [ ] Unmet need
   - [ ] Life-threatening condition
   - [ ] Long-term data needed
   - [ ] Only feasible to conduct post-approval
   - [ ] Prior clinical experience indicates safety
   - [ ] Small subpopulation affected
   - [ ] Theoretical concern
   - [x] Other

   The drug is ready for approval in adults and study in adolescent patients 12 to less than 18 years is not complete.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
3. If the study/clinical trial is a PMR, check the applicable regulation.  
*If not a PMR, skip to 4.*

- **Which regulation?**
  - Accelerated Approval (subpart H/E)
  - Animal Efficacy Rule
  - Pediatric Research Equity Act
  - FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - Assess a known serious risk related to the use of the drug?
  - Assess signals of serious risk related to the use of the drug?
  - Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - Analysis of spontaneous postmarketing adverse events?  
    *Do not select the above study/clinical trial type if:* such an analysis will not be sufficient to assess or identify a serious risk
  
  - Analysis using pharmacovigilance system?  
    *Do not select the above study/clinical trial type if:* the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk
  
  - Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
    *Do not select the above study type if:* a study will not be sufficient to identify or assess a serious risk
  
  - Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

Conduct the deferred pediatric study to assess the pharmacokinetics, safety/tolerability, and antiviral activity of tenofovir alafenamide in HBV infected subjects 12 to less than 18 years of age, followed by a rollover to a long-term, open-label, extension to assess longer-term pediatric safety and antiviral activity.
Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☒ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
☐ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☐ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials

Continuation of Question 4

☐ Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☐ Other (provide explanation)

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☐ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)

☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?

☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
☒ Are the objectives clear from the description of the PMR/PMC?
☒ Has the applicant adequately justified the choice of schedule milestone dates?
☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

☐ Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

If so, does the clinical trial meet the following criteria?

☐ There is a significant question about the public health risks of an approved drug
☐ There is not enough existing information to assess these risks
☐ Information cannot be gained through a different kind of investigation
☐ The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and the trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

☒ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

_______________________________________

(signature line for BLAs)
This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA #: 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet

PMR Description:
Conduct the deferred pediatric study to assess the pharmacokinetics, safety/tolerability, and antiviral activity of tenofovir alafenamide in HBV infected subjects 2 to less than 12 years of age, followed by a rollover to a long-term, open-label, extension to assess longer-term pediatric safety and antiviral activity.

PMR Schedule Milestones:
- Final Protocol Submission: January 2018
- Study/Trial Completion: September 2021
- Final Report Submission: March 2022
- Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

- [ ] Unmet need
- [ ] Life-threatening condition
- [ ] Long-term data needed
- [ ] Only feasible to conduct post-approval
- [ ] Prior clinical experience indicates safety
- [ ] Small subpopulation affected
- [ ] Theoretical concern
- [x] Other

The drug is ready for approval in adults and study in pediatric patients 2 to less than 12 years is not complete.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
The goal of the deferred study is to determine the PK profile of VEMLIDY® in pediatric patients 2 to less than 12 years of age, confirm the dose that results in exposure similar to that found to be safe and effective in adult patients, and provide safety information in this pediatric age group. An assessment of antiviral activity will be performed to further support extrapolation of efficacy from the adult clinical trials.

3. If the study/clinical trial is a PMR, check the applicable regulation.
   If not a PMR, skip to 4.
   - Which regulation?
     - Accelerated Approval (subpart H/E)
     - Animal Efficacy Rule
     - Pediatric Research Equity Act
     - FDAAA required safety study/clinical trial

   - If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)
     - Assess a known serious risk related to the use of the drug?
     - Assess signals of serious risk related to the use of the drug?
     - Identify an unexpected serious risk when available data indicate the potential for a serious risk?

   - If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:
     - Analysis of spontaneous postmarketing adverse events?
       Do not select the above study/clinical trial type if: such an analysis will not be sufficient to assess or identify a serious risk
     - Analysis using pharmacovigilance system?
       Do not select the above study/clinical trial type if: the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk
     - Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
       Do not select the above study type if: a study will not be sufficient to identify or assess a serious risk
     - Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

   Conduct the deferred pediatric study to access the pharmacokinetics, safety/tolerability, and antiviral activity of tenofovir alafenamide in HBV infected subjects 2 to less than 12 years of age, followed by a rollover to a long-term, open-label, extension to assess longer-term pediatric safety and antiviral activity.
Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☒ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
☐ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☐ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials

Continuation of Question 4

☐ Additional data or analysis required for a previously submitted or expected study/clinical trial
   (provide explanation)

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☐ Other (provide explanation)

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☐ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)

☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?

☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
☒ Are the objectives clear from the description of the PMR/PMC?
☒ Has the applicant adequately justified the choice of schedule milestone dates?
☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

☐ Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

If so, does the clinical trial meet the following criteria?

☐ There is a significant question about the public health risks of an approved drug
☐ There is not enough existing information to assess these risks
☐ Information cannot be gained through a different kind of investigation
☐ The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
☐ The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

☑ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

_______________________________________
(signature line for BLAs)
This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA #: 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet

PMR Description:
Perform genotypic (also phenotypic if qualified) resistance analysis of baseline virus samples from all HBeAg-positive nucleos(t)ide reverse transcriptase inhibitor-experienced subjects and of Week-48 virus samples from all evaluable subjects in Study GS-US-320-0110, regardless of their Week 96 virologic outcome. Genotyping should be conducted using Next Generation Sequence analysis.

PMR Schedule Milestones:
Final Protocol Submission: N/A
Study/Trial Completion: N/A
Final Report Submission: June 2017
Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

☐ Unmet need
☐ Life-threatening condition
☐ Long-term data needed
☐ Only feasible to conduct post-approval
☐ Prior clinical experience indicates safety
☐ Small subpopulation affected
☒ Theoretical concern
☐ Other

We are requesting additional resistance analysis of baseline and Week-48 virus samples from subjects who responded poorly to treatment to identify amino acid substitutions in the HBV rt domain predictive of treatment failure.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
The goal of this study is to define resistance pathways for tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF).

3. If the study/clinical trial is a PMR, check the applicable regulation.
   
   **If not a PMR, skip to 4.**

   - **Which regulation?**
     - [ ] Accelerated Approval (subpart H/E)
     - [ ] Animal Efficacy Rule
     - [ ] Pediatric Research Equity Act
     - [X] FDAAA required safety study/clinical trial

   - **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
     - [ ] Assess a known serious risk related to the use of the drug?
     - [ ] Assess signals of serious risk related to the use of the drug?
     - [X] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

   - **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
     - [ ] Analysis of spontaneous postmarketing adverse events?
       **Do not select the above study/clinical trial type if:** such an analysis will not be sufficient to assess or identify a serious risk

     - [ ] Analysis using pharmacovigilance system?
       **Do not select the above study/clinical trial type if:** the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk

     - [X] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
       **Do not select the above study type if:** a study will not be sufficient to identify or assess a serious risk

     - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

   Perform genotypic (also phenotypic if qualified) resistance analysis of baseline and Week-48 virus samples from all HBeAg-positive nucleos(id)ide reverse transcriptase inhibitor-experienced subjects who failed to respond to treatment.
Required

- Observational pharmacoepidemiologic study
- Registry studies
- Primary safety study or clinical trial
- Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
- Thorough Q-T clinical trial
- Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
- Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
- Pharmacokinetic studies or clinical trials
- Drug interaction or bioavailability studies or clinical trials
- Dosing trials

Continuation of Question 4

- Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)
  - Additional resistance data are required for a subset of subjects who showed poor response to TAF or TDF treatment.
- Meta-analysis or pooled analysis of previous studies/clinical trials
- Immunogenicity as a marker of safety
- Other (provide explanation)

Agreed upon:

- Quality study without a safety endpoint (e.g., manufacturing, stability)
- Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
- Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
- Dose-response study or clinical trial performed for effectiveness
- Nonclinical study, not safety-related (specify)
- Other

5. Is the PMR/PMC clear, feasible, and appropriate?

- Does the study/clinical trial meet criteria for PMRs or PMCs?
- Are the objectives clear from the description of the PMR/PMC?
- Has the applicant adequately justified the choice of schedule milestone dates?
- Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

- Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

*If so, does the clinical trial meet the following criteria?*

- There is a significant question about the public health risks of an approved drug
- There is not enough existing information to assess these risks
- Information cannot be gained through a different kind of investigation
- The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
- The trial will emphasize risk minimization for participants as the protocol is developed

Reference ID: 4007375
PMR/PMC Development Coordinator:

This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

(signature line for BLAs)
This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA # 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet

PMR Description: Conduct a cell-culture 2-drug combination study to evaluate the anti-HBV activity of tenofovir alafenamide (TAF) in combination with sofosbuvir.

PMR Schedule Milestones:
Final Protocol Submission: N/A
Study/Trial Completion: N/A
Final Report Submission: June 2017
Other: N/A N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

☐ Unmet need
☐ Life-threatening condition
☐ Long-term data needed
☐ Only feasible to conduct post-approval
☐ Prior clinical experience indicates safety
☐ Small subpopulation affected
☒ Theoretical concern
☐ Other

We are requesting a cell-culture 2-drug combination study to evaluate the potential antagonistic effect of sofosbuvir (HCV nucleotide analog NS5B polymerase inhibitor) on the anti-HBV activity of TAF. The treatment response of the HBV-infected individuals co-infected with HCV could be impacted if sofosbuvir is antagonistic to the anti-HBV activity of TAF.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
3. If the study/clinical trial is a PMR, check the applicable regulation.  
*If not a PMR, skip to 4.*

- **Which regulation?**
  - [ ] Accelerated Approval (subpart H/E)
  - [ ] Animal Efficacy Rule
  - [ ] Pediatric Research Equity Act
  - [x] FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - [ ] Assess a known serious risk related to the use of the drug?
  - [ ] Assess signals of serious risk related to the use of the drug?
  - [x] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - [ ] Analysis of spontaneous postmarketing adverse events?  
    *Do not select the above study/clinical trial type if:* such an analysis will not be sufficient to assess or identify a serious risk

  - [ ] Analysis using pharmacovigilance system?  
    *Do not select the above study/clinical trial type if:* the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk

  - [x] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?  
    *Do not select the above study type if:* a study will not be sufficient to identify or assess a serious risk

  - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

Conduct a cell-culture 2-drug combination study to evaluate the anti-HBV activity of TAF in combination with sofosbuvir.
Required

- Observational pharmacoepidemiologic study
- Registry studies
- Primary safety study or clinical trial
- Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
- Thorough Q-T clinical trial
- Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
- Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
- Pharmacokinetic studies or clinical trials
- Drug interaction or bioavailability studies or clinical trials
- Dosing trials

Continuation of Question 4

- Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)
- Meta-analysis or pooled analysis of previous studies/clinical trials
- Immunogenicity as a marker of safety
- Other (provide explanation)

Agreed upon:

- Quality study without a safety endpoint (e.g., manufacturing, stability)
- Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
- Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
- Dose-response study or clinical trial performed for effectiveness
- Nonclinical study, not safety-related (specify)

- Other

5. Is the PMR/PMC clear, feasible, and appropriate?

- Does the study/clinical trial meet criteria for PMRs or PMCs?
- Are the objectives clear from the description of the PMR/PMC?
- Has the applicant adequately justified the choice of schedule milestone dates?
- Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

- Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

If so, does the clinical trial meet the following criteria?

- There is a significant question about the public health risks of an approved drug
- There is not enough existing information to assess these risks
- Information cannot be gained through a different kind of investigation
- The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
- The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

☒ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

______________________________
(signature line for BLAs)
PMR/PMC Development Template

This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA # 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet
PMR Description: To evaluate potential tenofovir alafenamide (TAF) resistance pathways, sequence the baseline and Week 48 time-points (by population sequencing or NGS) for all evaluable subjects who had HBV DNA >69 IU/mL and provide a study report that includes resistance data analysis.

PMR Schedule Milestones:
- Final Protocol Submission: N/A
- Study/Trial Completion: N/A
- Final Report Submission: June 2017
- Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

☐ Unmet need
☐ Life-threatening condition
☐ Long-term data needed
☐ Only feasible to conduct post-approval
☐ Prior clinical experience indicates safety
☐ Small subpopulation affected
☒ Theoretical concern
☐ Other

Resistance pathways for TAF have not been clearly defined due to the lack of treatment-emergent amino acid substitutions identified in clinical trials from the virus of subjects who failed or responded poorly to treatment. We are requesting additional sequencing of viral proteins from virologic failures to see if amino acid substitutions can be correlated with resistance.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”

Reference ID: 4007375
3. If the study/clinical trial is a PMR, check the applicable regulation. **If not a PMR, skip to 4.**

- **Which regulation?**
  - [ ] Accelerated Approval (subpart H/E)
  - [ ] Animal Efficacy Rule
  - [ ] Pediatric Research Equity Act
  - [x] FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - [ ] Assess a known serious risk related to the use of the drug?
  - [ ] Assess signals of serious risk related to the use of the drug?
  - [x] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - [ ] Analysis of spontaneous postmarketing adverse events?
    **Do not select the above study/clinical trial type if:** such an analysis will not be sufficient to assess or identify a serious risk
  - [ ] Analysis using pharmacovigilance system?
    **Do not select the above study/clinical trial type if:** the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk
  - [x] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
    **Do not select the above study type if:** a study will not be sufficient to identify or assess a serious risk
  - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

Sequencing of baseline and Week 48 time-points (by population sequencing or NGS) for all evaluable subjects who had HBV DNA >69 IU/mL in the two pivotal clinical trials reviewed under this NDA. The sponsor provided sequencing for most but not all subjects, and additional sequencing information is needed to determine if there are any definable resistance pathways.

Defining resistance pathways for a drug is important for efficacy and safety. The goal of this request is to gather additional information from a small subset of subjects that will help inform the resistance profile for this drug.
Required
☐ Observational pharmacoepidemiologic study
☐ Registry studies
☐ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
☒ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☐ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials

Continuation of Question 4

☒ Additional data or analysis required for a previously submitted or expected study/clinical trial
        (provide explanation)
        We are requesting additional sequencing information for a subset of subjects who failed to respond or responded poorly to treatment with TAF.
☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☐ Other (provide explanation)

Agreed upon:
☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☐ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)
☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?
☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
☒ Are the objectives clear from the description of the PMR/PMC?
☒ Has the applicant adequately justified the choice of schedule milestone dates?
☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?
☐ Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

If so, does the clinical trial meet the following criteria?
☐ There is a significant question about the public health risks of an approved drug
☐ There is not enough existing information to assess these risks
☐ Information cannot be gained through a different kind of investigation
☐ The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
☐ The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

☒ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

______________________________
(signature line for BLAs)
PMR/PMC Development Template

This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA # 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet

PMR Description: To evaluate potential tenofovir alafenamide (TAF) resistance pathways and provide a study report that includes resistance data analysis for evaluable samples at baseline, Week 48 and Week 96 and submit the fastq files and analyses for subjects 4296-4510, 5613-1163, and 9035-5187, that had HBV DNA titers at the last PCR assessment that were >159 IU/mL, qualifying them for deep sequencing analysis.

PMR Schedule Milestones:
- Final Protocol Submission: N/A
- Study/Trial Completion: N/A
- Final Report Submission: June 2017
- Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

☐ Unmet need
☐ Life-threatening condition
☐ Long-term data needed
☐ Only feasible to conduct post-approval
☐ Prior clinical experience indicates safety
☐ Small subpopulation affected
☒ Theoretical concern
☐ Other

Resistance pathways for TAF have not been clearly defined due to the lack of treatment-emergent amino acid substitutions identified in clinical trials from the virus of subjects who failed or responded poorly to treatment. We are requesting additional sequencing of viral proteins from virologic failures to see if amino acid substitutions can be correlated with resistance.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”

Reference ID: 4007375
3. If the study/clinical trial is a PMR, check the applicable regulation. 
*If not a PMR, skip to 4.*

- **Which regulation?**
  - [ ] Accelerated Approval (subpart H/E)
  - [ ] Animal Efficacy Rule
  - [ ] Pediatric Research Equity Act
  - [x] FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - [ ] Assess a known serious risk related to the use of the drug?
  - [ ] Assess signals of serious risk related to the use of the drug?
  - [x] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - [ ] Analysis of spontaneous postmarketing adverse events? *Do not select the above study/clinical trial type if: such an analysis will not be sufficient to assess or identify a serious risk*
  - [ ] Analysis using pharmacovigilance system? *Do not select the above study/clinical trial type if: the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk*
  - [x] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments? *Do not select the above study type if: a study will not be sufficient to identify or assess a serious risk*
  - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. **What type of study or clinical trial is required or agreed upon (describe and check type below)?** If the study or trial will be performed in a subpopulation, list here.

Subjects 4296-4510, 5613-1163, and 9035-5187 had HBV DNA titers at the last PCR assessment that were >159 IU/mL, qualifying them for deep sequencing analysis. Sequencing of samples derived from Week 48, Week 96, or both of these three subjects to further evaluate resistance pathways to determine if there are any definable resistance pathways.

Defining resistance pathways for a drug is important for efficacy and safety. The goal of this request is to gather additional information from a small subset of subjects that will help inform the resistance profile for this drug.
Required

- Observational pharmacoepidemiologic study
- Registry studies
- Primary safety study or clinical trial
- Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
- Thorough Q-T clinical trial
- Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
- Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
- Pharmacokinetic studies or clinical trials
- Drug interaction or bioavailability studies or clinical trials
- Dosing trials

*Continuation of Question 4*

- Additional data or analysis required for a previously submitted or expected study/clinical trial
  (provide explanation)
  - We are requesting additional sequencing information for three subjects who failed to respond
  or responded poorly to treatment with TAF.

- Meta-analysis or pooled analysis of previous studies/clinical trials
- Immunogenicity as a marker of safety
- Other (provide explanation)

Agreed upon:

- Quality study without a safety endpoint (e.g., manufacturing, stability)
- Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background
  rates of adverse events)
- Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease
  severity, or subgroup) that are NOT required under Subpart H/E
- Dose-response study or clinical trial performed for effectiveness
- Nonclinical study, not safety-related (specify)

- Other

5. Is the PMR/PMC clear, feasible, and appropriate?

- Does the study/clinical trial meet criteria for PMRs or PMCs?
- Are the objectives clear from the description of the PMR/PMC?
- Has the applicant adequately justified the choice of schedule milestone dates?
- Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility,
  and contribute to the development process?

- Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

*If so, does the clinical trial meet the following criteria?*

- There is a significant question about the public health risks of an approved drug
- There is not enough existing information to assess these risks
- Information cannot be gained through a different kind of investigation
- The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
- The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

(signature line for BLAs)
PMR/PMC Development Template

This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA #: 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet

PMR Description: Provide a study report that includes resistance data analysis and submit the fastq files and analyses for subjects 8006-5282 and 8600-4558 who had HBV DNA titers at the last PCR assessment that were >159 IU/mL.

PMR Schedule Milestones:
- Final Protocol Submission: N/A
- Study/Trial Completion: N/A
- Final Report Submission: June 2017
- Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

☐ Unmet need
☐ Life-threatening condition
☐ Long-term data needed
☐ Only feasible to conduct post-approval
☐ Prior clinical experience indicates safety
☐ Small subpopulation affected
☒ Theoretical concern
☐ Other

Resistance pathways for TAF have not been clearly defined due to the lack of treatment-emergent amino acid substitutions identified in clinical trials from the virus of subjects who failed or responded poorly to treatment. We are requesting additional sequencing of viral proteins from subjects who failed to see if amino acid substitutions can be correlated with resistance.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
3. If the study/clinical trial is a PMR, check the applicable regulation. 
*If not a PMR, skip to 4.*

- **Which regulation?**
  - [ ] Accelerated Approval (subpart H/E)
  - [ ] Animal Efficacy Rule
  - [ ] Pediatric Research Equity Act
  - [x] FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - [ ] Assess a known serious risk related to the use of the drug?
  - [ ] Assess signals of serious risk related to the use of the drug?
  - [x] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - [ ] Analysis of spontaneous postmarketing adverse events?
    
    *Do not select the above study/clinical trial type if:* such an analysis will not be sufficient to assess or identify a serious risk

  - [ ] Analysis using pharmacovigilance system?
    
    *Do not select the above study/clinical trial type if:* the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk

  - [x] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?
    
    *Do not select the above study type if:* a study will not be sufficient to identify or assess a serious risk

  - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

   **Sequencing of the last evaluable samples for two subjects who failed treatment with TAF to further evaluate potential resistance pathways for these subjects.**
Required
☐ Observational pharmacoepidemiologic study
☐ Registry studies
☐ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
☒ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☐ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials

Continuation of Question 4

☒ Additional data or analysis required for a previously submitted or expected study/clinical trial
  (provide explanation)
  We are requesting additional sequencing information for a subset of subjects who failed to respond or responded poorly to treatment with TAF.
☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☐ Other (provide explanation)

Agreed upon:
☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☐ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)
☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?
☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
☒ Are the objectives clear from the description of the PMR/PMC?
☒ Has the applicant adequately justified the choice of schedule milestone dates?
☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

☐ Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

If so, does the clinical trial meet the following criteria?
☐ There is a significant question about the public health risks of an approved drug
☐ There is not enough existing information to assess these risks
☐ Information cannot be gained through a different kind of investigation
☐ The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
☐ The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

(signature line for BLAs)
This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

<table>
<thead>
<tr>
<th>NDA/BLA #</th>
<th>208464/Original Submission</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name:</td>
<td>VEMLIDY® (tenofovir alafenamide), 25 mg tablet</td>
</tr>
<tr>
<td>PMC Description:</td>
<td>Phenotype Week-48 virus samples from Subjects 4296-5147 and 8758-5188 in the tenofovir alafenamide (TAF) group and Subjects 1507-4546 and 9035-4845 in the tenofovir disoproxil fumarate (TDF) group in Study GS-US-320-0110.</td>
</tr>
<tr>
<td>PMC Schedule Milestones:</td>
<td>Final Protocol Submission: N/A</td>
</tr>
<tr>
<td></td>
<td>Study/Trial Completion: N/A</td>
</tr>
<tr>
<td></td>
<td>Final Report Submission: June 2017</td>
</tr>
<tr>
<td></td>
<td>Other: N/A</td>
</tr>
</tbody>
</table>

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

- [ ] Unmet need
- [ ] Life-threatening condition
- [ ] Long-term data needed
- [ ] Only feasible to conduct post-approval
- [ ] Prior clinical experience indicates safety
- [ ] Small subpopulation affected
- [ ] Theoretical concern
- [ ] Other

We are requesting additional phenotypic resistance data of virus samples from subjects who failed treatment to identify amino acid substitutions that confer reduced susceptibility to study drugs.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
The goal of this study is to identify amino acid substitutions that confer reduced susceptibility to study drugs.

3. If the study/clinical trial is a PMR, check the applicable regulation.  
   **If not a PMR, skip to 4.**
   - **Which regulation?**
     - [ ] Accelerated Approval (subpart H/E)
     - [ ] Animal Efficacy Rule
     - [ ] Pediatric Research Equity Act
     - [ ] FDAAA required safety study/clinical trial
   - **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
     - [ ] Assess a known serious risk related to the use of the drug?
     - [ ] Assess signals of serious risk related to the use of the drug?
     - [ ] Identify an unexpected serious risk when available data indicate the potential for a serious risk?
   - **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
     - [ ] Analysis of spontaneous postmarketing adverse events?  
       **Do not select the above study/clinical trial type if:** such an analysis will not be sufficient to assess or identify a serious risk
     - [ ] Analysis using pharmacovigilance system?  
       **Do not select the above study/clinical trial type if:** the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk
     - [ ] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?  
       **Do not select the above study type if:** a study will not be sufficient to identify or assess a serious risk
     - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?
   4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

   Phenotype Week-48 virus samples from Subjects 4296-5147 and 8758-5188 in the TAF group and Subjects 1507-4546 and 9035-4845 in the TDF group in Study GS-US-320-0110.
Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☐ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
☒ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☐ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials

Continuation of Question 4

☒ Additional data or analysis required for a previously submitted or expected study/clinical trial (provide explanation)
   We are requesting phenotypic data of Week-48 virus samples from subjects who failed to respond to treatment in Study GS-US-320-0110.

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☐ Other (provide explanation)

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☐ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)

☐ Other

5. Is the PMR/PMC clear, feasible, and appropriate?

☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
☒ Are the objectives clear from the description of the PMR/PMC?
☒ Has the applicant adequately justified the choice of schedule milestone dates?
☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

☐ Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

*If so, does the clinical trial meet the following criteria?*

☐ There is a significant question about the public health risks of an approved drug
☐ There is not enough existing information to assess these risks
☐ Information cannot be gained through a different kind of investigation
☐ The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
☐ The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

☑️ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

_______________________________________

(signature line for BLAs)
PMR/PMC Development Template

This template should be completed by the PMR/PMC Development Coordinator and included for each PMR/PMC in the Action Package.

NDA/BLA #: 208464/Original Submission
Product Name: VEMLIDY® (tenofovir alafenamide), 25 mg tablet

PMC Description: Submit the long-term efficacy, safety and antiviral activity data for Studies GS-US-320-0108 and GS-US-320-0110. Include data and analyses for the entire study population through Week 144.

PMC Schedule Milestones:
- Final Protocol Submission: May 2013 (submitted)
- Study/Trial Completion: September 2017
- Final Report Submission: March 2018
- Other: N/A

1. During application review, explain why this issue is appropriate for a PMR/PMC instead of a pre-approval requirement. Check type below and describe.

- [ ] Unmet need
- [ ] Life-threatening condition
- [X] Long-term data needed
- [ ] Only feasible to conduct post-approval
- [ ] Prior clinical experience indicates safety
- [ ] Small subpopulation affected
- [ ] Theoretical concern
- [ ] Other

The study data requested represents long-term, follow-up data that will support the safety of dosing VEMLIDY® for longer than 48 weeks (the duration of therapy included in the NDA submission). Because HBV requires continuous treatment, it is important to characterize the durability of treatment response and/or delayed adverse effects to inform treatment guidelines and clinical practice.

2. Describe the particular review issue and the goal of the study/clinical trial. If the study/clinical trial is a FDAAA PMR, describe the risk. If the FDAAA PMR is created post-approval, describe the “new safety information.”
The study data requested will provide long-term, follow-up data that will support the safety of dosing VEMLIDY® for longer than 48 weeks (the duration of therapy included in the NDA submission). Because HBV requires continuous treatment, it is important to characterize the durability of treatment response and/or delayed adverse effects to inform treatment guidelines and clinical practice.

3. If the study/clinical trial is a PMR, check the applicable regulation.  
*If not a PMR, skip to 4.*

- **Which regulation?**
  - [ ] Accelerated Approval (subpart H/E)
  - [ ] Animal Efficacy Rule
  - [ ] Pediatric Research Equity Act
  - [ ] FDAAA required safety study/clinical trial

- **If the PMR is a FDAAA safety study/clinical trial, does it: (check all that apply)**
  - [ ] Assess a known serious risk related to the use of the drug?
  - [ ] Assess signals of serious risk related to the use of the drug?
  - [ ] Identify an unexpected serious risk when available data indicate the potential for a serious risk?

- **If the PMR is a FDAAA safety study/clinical trial, will it be conducted as:**
  - [ ] Analysis of spontaneous postmarketing adverse events?  
    *Do not select the above study/clinical trial type if:*
    such an analysis will not be sufficient to assess or identify a serious risk
  - [ ] Analysis using pharmacovigilance system?  
    *Do not select the above study/clinical trial type if:*
    the new pharmacovigilance system that the FDA is required to establish under section 505(k)(3) has not yet been established and is thus not sufficient to assess this known serious risk, or has been established but is nevertheless not sufficient to assess or identify a serious risk
  - [ ] Study: all other investigations, such as investigations in humans that are not clinical trials as defined below (e.g., observational epidemiologic studies), animal studies, and laboratory experiments?  
    *Do not select the above study type if:*
    a study will not be sufficient to identify or assess a serious risk
  - [ ] Clinical trial: any prospective investigation in which the sponsor or investigator determines the method of assigning investigational product or other interventions to one or more human subjects?

4. What type of study or clinical trial is required or agreed upon (describe and check type below)? If the study or trial will be performed in a subpopulation, list here.

Submit the long-term efficacy, safety and antiviral activity data for Studies GS-US-320-0108 and GS-US-320-0110. Include data and analyses for the entire study population through Week 144,
Required

☐ Observational pharmacoepidemiologic study
☐ Registry studies
☒ Primary safety study or clinical trial
☐ Pharmacogenetic or pharmacogenomic study or clinical trial if required to further assess safety
☐ Thorough Q-T clinical trial
☐ Nonclinical (animal) safety study (e.g., carcinogenicity, reproductive toxicology)
☐ Nonclinical study (laboratory resistance, receptor affinity, quality study related to safety)
☐ Pharmacokinetic studies or clinical trials
☐ Drug interaction or bioavailability studies or clinical trials
☐ Dosing trials

Continuation of Question 4

☐ Additional data or analysis required for a previously submitted or expected study/clinical trial
  (provide explanation)

☐ Meta-analysis or pooled analysis of previous studies/clinical trials
☐ Immunogenicity as a marker of safety
☐ Other (provide explanation)

Agreed upon:

☐ Quality study without a safety endpoint (e.g., manufacturing, stability)
☐ Pharmacoepidemiologic study not related to safe drug use (e.g., natural history of disease, background rates of adverse events)
☐ Clinical trials primarily designed to further define efficacy (e.g., in another condition, different disease severity, or subgroup) that are NOT required under Subpart H/E
☐ Dose-response study or clinical trial performed for effectiveness
☐ Nonclinical study, not safety-related (specify)
☒ Other
  Long-term extension phase data from ongoing clinical trials

5. Is the PMR/PMC clear, feasible, and appropriate?

☒ Does the study/clinical trial meet criteria for PMRs or PMCs?
☒ Are the objectives clear from the description of the PMR/PMC?
☒ Has the applicant adequately justified the choice of schedule milestone dates?
☒ Has the applicant had sufficient time to review the PMRs/PMCs, ask questions, determine feasibility, and contribute to the development process?

☐ Check if this form describes a FDAAA PMR that is a randomized controlled clinical trial

If so, does the clinical trial meet the following criteria?

☐ There is a significant question about the public health risks of an approved drug
☐ There is not enough existing information to assess these risks
☐ Information cannot be gained through a different kind of investigation
☐ The trial will be appropriately designed to answer question about a drug’s efficacy and safety, and
☐ The trial will emphasize risk minimization for participants as the protocol is developed
PMR/PMC Development Coordinator:

☑ This PMR/PMC has been reviewed for clarity and consistency, and is necessary to further refine the safety, efficacy, or optimal use of a drug, or to ensure consistency and reliability of drug quality.

______________________________

(signature line for BLAs)
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MYUNG JOO P HONG
11/01/2016
Date: October 27, 2016

To: Debra Birnkrant, MD
    Director
    Division of Antiviral Products (DAVP)

Through: LaShawn Griffths, MSHS-PH, BSN, RN
    Associate Director for Patient Labeling
    Division of Medical Policy Programs (DMPP)

Barbara Fuller, RN, MSN, CWOCN
    Team Leader, Patient Labeling
    Division of Medical Policy Programs (DMPP)

From: Rowell Medina, PharmD, BCPS
    Patient Labeling Reviewer
    Division of Medical Policy Programs (DMPP)

Wendy Lubarsky, PharmD
    Regulatory Review Officer
    Office of Prescription Drug Promotion (OPDP)

Subject: Review of Patient Labeling: Patient Package Insert (PPI)

Drug Name (established name): VEMLIDY (tenofovir alafenamide)

Dosage Form and Route: tablets, for oral use

Application Type/Number: NDA 208464

Applicant: Gilead Sciences, Inc.
1 INTRODUCTION

On January 11, 2016, Gilead Sciences, Inc. submitted for the Agency’s review a New Drug Application (NDA) 208464 for VEMLIDY (tenofovir alafenamide) tablets. The proposed indication for VEMLIDY (tenofovir alafenamide) tablets is for the treatment of chronic hepatitis B in adults.

This collaborative review is written by the Division of Medical Policy Programs (DMPP) and the Office of Prescription Drug Promotion (OPDP) in response to a request by the Division of Antiviral Products (DAVP) on January 12, 2016 for DMPP and OPDP to review the Applicant’s proposed Patient Package Insert (PPI) for VEMLIDY (tenofovir alafenamide) tablets.

2 MATERIAL REVIEWED

- Draft VEMLIDY (tenofovir alafenamide) tablets PPI received on January 11, 2016, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on October 24, 2016.

- Draft VEMLIDY (tenofovir alafenamide) tablets Prescribing Information (PI) received on January 11, 2016, revised by the Review Division throughout the review cycle, and received by DMPP and OPDP on October 24, 2016.

3 REVIEW METHODS

To enhance patient comprehension, materials should be written at a 6th to 8th grade reading level, and have a reading ease score of at least 60%. A reading ease score of 60% corresponds to an 8th grade reading level. In our review of the PPI the target reading level is at or below an 8th grade level.

Additionally, in 2008 the American Society of Consultant Pharmacists Foundation (ASCP) in collaboration with the American Foundation for the Blind (AFB) published Guidelines for Prescription Labeling and Consumer Medication Information for People with Vision Loss. The ASCP and AFB recommended using fonts such as Verdana, Arial or APHont to make medical information more accessible for patients with vision loss. We reformatted the PPI document using the Arial font, size 10.

In our collaborative review of the PPI we:

- simplified wording and clarified concepts where possible
- ensured that the PPI is consistent with the Prescribing Information (PI)
- removed unnecessary or redundant information
- ensured that the PPI is free of promotional language or suggested revisions to ensure that it is free of promotional language
- ensured that the PPI meets the criteria as specified in FDA’s Guidance for Useful Written Consumer Medication Information (published July 2006)
4 CONCLUSIONS
The PPI is acceptable with our recommended changes.

5 RECOMMENDATIONS
- Please send these comments to the Applicant and copy DMPP and OPDP on the correspondence.
- Our collaborative review of the PPI is appended to this memorandum. Consult DMPP and OPDP regarding any additional revisions made to the PI to determine if corresponding revisions need to be made to the PPI.

Please let us know if you have any questions.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROWELL MEDINA  
10/27/2016

WENDY R LUBARSKY  
10/27/2016

BARBARA A FULLER  
10/27/2016

LASHAWN M GRIFFITHS  
10/27/2016
Memorandum

Date: October 27, 2016

To: Myung-Joo Patricia Hong, MS
Senior Regulatory Project Manager
Division of Antiviral Products

From: Wendy Lubarsky, PharmD, Regulatory Review Officer
Office of Prescription Drug Promotion

Subject: NDA 208464 – VEMLIDY (tenofovir alafenamide) tablets, for oral use

As requested in the Division of Antiviral Products’ (DAVP) consult dated January 12, 2016, the Office of Prescription Drug Promotion (OPDP) has reviewed the VEMLIDY prescribing information and patient labeling.

OPDP reviewed the proposed substantially complete version of the prescribing information sent via email on October 24, 2016, and has provided comments in the labeling attached to this document.

The Division of Medical Policy Programs and OPDP provided a single, consolidated review of the patient labeling on October 27, 2016.

Thank you for your consult. OPDP appreciates the opportunity to provide comments. If you have any questions, please contact Wendy Lubarsky at (204) 402-7721 or Wendy.Lubarsky@fda.hhs.gov.

26 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

WENDY R LUBARSKY
10/27/2016
MEMORANDUM
REVIEW OF REVISED LABEL AND LABELING
Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

Date of This Memorandum: September 29, 2016
Requesting Office or Division: Division of Antiviral Products (DAVP)
Application Type and Number: NDA 208464
Product Name and Strength: Vemlidy
(tenofovir alafenamide) Tablets
25 mg
Submission Date: July 7, 2016
Applicant/Sponsor Name: Gilead Sciences, Inc.
OSE RCM #: 2016-107-1
DMEPA Primary Reviewer: Mónica Calderón, PharmD, BCPS
DMEPA Team Leader: Vicky Borders-Hemphill, PharmD

1 PURPOSE OF MEMO
Gilead Sciences, Inc has submitted the revised container label (Appendix A) and Full Prescribing Information (FPI) for Vemlidy in response to recommendations we made during a previous label and labeling review. Thus, the Division of Antiviral Products (DAVP) requested that we review the revised label and labeling to determine if it is acceptable from a medication error perspective.

2 CONCLUSION
The Sponsor revised the container label and the FPI according to all of DMEPA’s recommendations. They are acceptable and we have no further recommendations at this time.

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MONICA M CALDERON  
09/29/2016

BRENDA V BORDERS-HEMPHILL  
09/30/2016
**Clinical Inspection Summary**

<table>
<thead>
<tr>
<th>Date</th>
<th>August 8, 2016</th>
</tr>
</thead>
</table>
| From          | Antoine El Hage, Ph.D. /OSI/DCCE/GCPAB  
               | Susan Thompson, M.D. /OSI/DCCE/GCPAB, Team Leader  
               | Kassa Ayalew, M.D., MPH. /OSI/DCCE/GCPAB, Branch Chief |
| To            | Patricia Myung-Joo, M.S. Senior Regulatory Health Project Manager  
               | Tanvir Bell, M.D., Medical Reviewer  
               | Russ Fleischer, PA-C, Acting CTDL  
               | Division of Antiviral Products (DAVP) |
| NDA/BLA #     | NDA 208464 |
| Applicant     | Gilead Sciences, Inc. |
| Drug          | Tenofovir alafenamide, Vemlidy (GS-7340) |
| NME (Yes/No)  | No |
| Therapeutic Classification | Standard |
| Proposed Indication(s) | Treatment of hepatitis B infection (HBV) |
| Consultation Request Date | February 12, 2016 |
| Summary Goal Date | October 11, 2016 |
| Action Goal Date | November 11, 2016 |
| PDUFA Date    | November 11, 2016 |

**I. OVERALL ASSESSMENT OF FINDINGS AND RECOMMENDATIONS**

The inspections for this NDA consisted of four foreign clinical sites. The inspection of four clinical investigators listed below revealed no regulatory violations.

The final classification for Drs. Chan, Yuen, and Fung is No Action Indicated (NAI). No regulatory violations were noted. Reliability of data form these sites is acceptable for use in support of the pending application.

The preliminary classification for Dr. Chuang is No Action Indicated (NAI). Data from this site is considered reliable based on the available information provided by the field investigator. An inspection summary addendum will be generated if conclusions change upon receipt and review of the pending EIR.

Based on the inspections of the four clinical sites, the inspectional findings support validity of the data as reported by the sponsor under this NDA.
II. BACKGROUND

Tenofovir alafenamide (TAF), a novel “intracellular” prodrug of tenofovir (TFV), has the potential to advance treatment of chronic HBV infection. Tenofovir alfenamide (TAF) is an oral formulation, available in these studies as a 25 mg tablet.


Inspections were requested for the following clinical studies:

**Protocol GS-US-320-0108**: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafemadine (TAF) 25 mg QD versus Tenofovir Disoproxil Fumurate (TDF) 300 mg QD for the Treatment of HBeAg-Negative, Chronic Hepatitis B

The primary objectives of this study were: 1) to compare the efficacy of tenofovir alafenamide (TAF) 25 mg QD versus tenofovir disoproxil fumurate (TDF) 300 mg QD for the treatment of HBeAg-negative, chronic hepatitis B at Week 48 in treatment-naïve and treatment-experienced subjects. The primary efficacy parameter was the proportion of subjects with plasma HBV DNA levels below 29 IU/mL, and 2) to compare the safety and tolerability of TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-negative, chronic hepatitis B at Week 48 in the treatment naïve and treatment experienced subjects.

This protocol was a randomized, double-blind, non-inferiority study to compare the antiviral activity of TAF 25 mg QD versus TDF 300 mg QD. A total of 105 sites enrolled subjects in the U.S. and worldwide. Approximately 390 subjects were randomized in a 2:1 ratio (A: B) to the treatment arms and were stratified by plasma HBV DNA level (less 7 log10 IU/mL and oral antiviral treatment status (naïve vs experienced) assigned as follows:

- Treatment Arm A: 260 subjects TAF 25 mg QD and matched placebo of TDF 300 mg QD.
- Treatment ARM B: 130 subjects TDF 300 mg QD and matched placebo of TAF 25 mg QD.

Subjects were randomized by evidence/presence of HBV infection for more than 6 months at screening. **Subjects with co-infection with HCV, HIV, or HDV, with malignancy or transplantation were excluded.** Note: Elevation of HBV-DNA without a corresponding increase in liver function test/ALT may indicate or be attributed to genotype mutation (relapse) and not to disease progression.

Number of subjects: 426 randomized; TAF 285 and TDF 141
Number of sites: 105
Participant countries: Worldwide and U.S.
First subject screened: September 12, 2913
Clinical Inspection Summary  
NDA [208464]  
[Tenofovir/Alafemadine]

Last subject observation for the report: September 30, 2015  
Last subject observation for primary endpoint: November 6, 2015

**Protocol GS-US-320-0110: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Tenofovir Alafemadine (TAF) 25 mg QD versus Tenofovir Disoproxil Fumurate (TDF) 300 mg QD for the Treatment of HBeAg-Positive, Chronic Hepatitis B**

The primary objectives of this study were: 1) to compare the efficacy of tenofovir alafenamide (TAF) 25 mg QD versus tenofovir disoproxil fumurate (TDF) 300 mg QD for the treatment of HBeAg-positive, chronic hepatitis B at Week 48 in treatment-naïve and treatment experienced subjects. The primary efficacy parameter was the proportion of subjects with plasma HBV DNA levels below 69 IU/mL, and 2) to compare the safety and tolerability of TAF 25 mg QD versus TDF 300 mg QD for the treatment of HBeAg-negative, chronic hepatitis B at Week 48 in the treatment naïve and treatment experienced subjects.

This protocol was a randomized, double-blind, non-inferiority study to compare the antiviral activity of TAF 25 mg QD versus TDF 300 mg QD. A total of 161 sites enrolled subjects both in the U.S. and worldwide. Approximately 864 subjects will be randomized in a 2:1 ratio (A:B) to the treatment arms for 48 weeks, and will be stratified by plasma HBV DNA level (> 8 log10 IU/mL) and oral antiviral treatment status (naïve vs experienced) assigned as follows:

- **Treatment Arm A:** 576 subjects TAF 25 mg QD or matched placebo of TDF 300 mg QD.
- **Treatment ARM B:** 288 subjects TDF 300 mg QD or matched placebo of TAF 25 mg QD.

Subjects were randomized by evidence/presence of HBV infection for 6 months at screening. *Subjects with co-infection with HCV, HIV, or HDV, with malignancy or transplantation were excluded.* Note: Elevation of HBV-DNA without a corresponding increase in liver function test/ALT may indicate or be attributed to genotype mutation (relapse) and not to disease progression.

Number of subjects: 874 randomized  
Number of sites: 161  
Participant countries: U.S. and Worldwide  
First subject screened: August 25, 2013  
Last observation report: November 16, 2015  
Last subject observation for the efficacy endpoint: September 24, 2015

The two trials were conducted in subjects with HBV and all utilized the same primary endpoint. Trial design was similar across studies but differed by HBeAg-negative and HBeAg-positive chronic hepatitis B. According to the sponsor, no significant drug related concerns were identified. Other reasons for foreign inspection are that this was the first approval of this new drug. Because HBV is more prevalent in Asia/Pacific than U.S., much of the limited...
experience with this drug in subjects infected with HBV has been at foreign sites.

The Sponsor’s interpretation of primary efficacy outcome: studies met the primary efficacy endpoint at high rates across the two trials. According to the sponsor, no significant drug related concerns were identified.

The CDER review division team with input from statistics was involved in the selection process. The sites were chosen principally due to high patient accrual in the two protocols: high rates of drop outs/protocol deviations, and high efficacy results. Except for Dr. Chung, no previous inspection history for the remaining three clinical investigators was found in our Database.

For Study GS-US-320-0108

Site #03076 Taiwan/Dr. Chung and Site #02757 in Hong Kong/Dr. Chan had a larger number of subjects and a high response rate.

For Study GS-US-329-0110

At Site #5691 in Hong Kong (Dr. Fung) and Site #2826 in Canada (Dr. Scott Fung), the response rates were also a little higher for TAF than for TDF.

III. RESULTS (by site):

<table>
<thead>
<tr>
<th>Name of CI, Site #, Address, Country if non-U.S. or City, State if U.S.</th>
<th>Protocol # and # of Subjects</th>
<th>Inspection Date</th>
<th>Final Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wan-Long, Chuang, M.D. Kaohsiung Medical Hospital Vhung Ho Memorial Hospital No 100 Tzyou 1 Road 21 F Chi-Chuan Frank Bld. Kaohsiung 807, Taiwan Site #3076</td>
<td>Astral-1 GS-US-320-0108 Subjects enrolled: 16</td>
<td>7/11-15/2016</td>
<td>NAI Preliminary</td>
</tr>
</tbody>
</table>
Man Fung, Yuen, M.D.  
Queen Mary Hospital, Rm. 303  
Wing E.Main Block  
102 Pokfulam Rd.  
Hong Kong  
Site #5691

<table>
<thead>
<tr>
<th>Location</th>
<th>Study Code</th>
<th>Subjects Enrolled</th>
<th>Date</th>
<th>Compliance Classifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Astral-2 GS-US-320-0110</td>
<td>44</td>
<td>6/6-8/2016</td>
<td>NAI</td>
<td></td>
</tr>
</tbody>
</table>

Scott Fung, M.D.  
Toronto General Hospital  
200 Elizabeth Street, Suite 9  
N981  
Toronto, Ontario M5G 2C4  
Canada  
Site #2826

<table>
<thead>
<tr>
<th>Location</th>
<th>Study Code</th>
<th>Subjects Enrolled</th>
<th>Date</th>
<th>Compliance Classifications</th>
</tr>
</thead>
</table>

Key to Compliance Classifications

NAI = No deviation from regulations.  
VAI = Deviation(s) from regulations.  
OAI = Significant deviations from regulations. Data are unreliable.  
Pending = Preliminary classification based on information in 483 or preliminary communication with the field; EIR has not been received from the field, and complete review of EIR is pending. Final classification occurs when the post-inspectional letter has been sent to the inspected entity.

NOTE: Site inspections focused on 100% review of informed consent documents, IRB, ethics committee correspondence, financial disclosures, training records, monitoring logs and reports, inclusion/exclusion criteria, enrollment logs, vital signs, subject source documents, including medical history records, drug accountability, and the use of concomitant medications. Source documents were compared to data listing for primary efficacy endpoints and adverse events reporting.

1. Henry Lik Yuen Chan, M.D./Site #2757 / Study GS-US-320-0108  
Prince of Wales Hospital  
Shatin, New Territories, Hong Kong

There were 38 subjects screened, 14 subjects were reported as screen failures, and 24 subjects were enrolled in the study. All 24 subjects completed the study, and all completed subjects continued on the study. The medical records for all subjects were reviewed for informed consent and primary efficacy endpoint; and 12 subjects’ records were reviewed for protocol compliance. Records were organized and legible. Medical records/source documents were compared to case report forms and data listings for primary efficacy endpoints and adverse event reporting. No deficiencies were found. The audit revealed adequate adherence to the regulations and investigational plan. There were no objectionable conditions noted and no Form FDA 483 was issued to Dr. Chan.
The data generated by this site appear acceptable. The inspection did not indicate serious deviations/findings that would impact the acceptability of the data submitted in support of the application.

2. **Man Fung, M.D./ Site #5691/Study GS-US-320-0108**
   Queen Mary Hospital
   102 Pokfulam Road
   Hong Kong

   There were 79 subjects screened, 35 subjects were reported as screen failures, 44 subjects enrolled in the study, and 39 subjects completed the study and are still continuing on the study. Five subjects were discontinued and the reason(s) were documented. For example, Subject #4808 due to pregnancy, Subject #4594 withdrew consent, Subject #5109 had hepatocellular cancer which resulted in death, Subject 5331 lost to follow-up, and Subject #5044 withdrew consent.

   The medical records for 22 subjects were reviewed. Records were organized and legible. Medical records/source documents were compared to data listings for primary efficacy endpoint and adverse events reporting. No deficiencies were observed. The audit revealed adequate adherence to the regulations and investigational plan. There were no objectionable conditions noted and no Form FDA 483 was issued to Dr. Yuen.

   Overall, the data generated at Dr. Yuen’s in support of the clinical efficacy and safety is considered acceptable and may be used in support of the pending application.

   21 F Chi-Chuan Frank Bld.
   Kaohsiung, 807 Taiwan

   There were 38 subjects screened, 15 subjects were reported as screen failures, 16 subjects were enrolled. There were no withdrawals/discontinuations or early termination. All 16 subjects completed the study. The medical records for all subjects were reviewed. Records were organized and legible. Medical records/source documents were compared to case report form and data listings for primary efficacy endpoint and adverse event reporting. No deficiencies were noted. The inspection revealed adequate adherence to the regulation and investigational plan. There were no objectionable conditions noted and no Form FDA-483, Inspectional Observations, was issued.

   The data generated by this site appear acceptable. The audit did not indicate serious deviations/findings that would impact the validity or reliability of the submitted data.

4. **Scott Fung/ Site #02826/ Study GS-US-320-0110**
Toronto General Hospital  
Toronto, ON MSG 2C4, Canada

There were 33 subjects screened and 27 subjects enrolled; 24 subjects completed the study and continued to participate. Six subjects failed screening due to eligibility criteria prior to randomization, or were lost to follow-up or discontinued for reasons well documented. For example, Subject #4527 was terminated due to family matters requiring return to the native country, China; Subject #4561 self-discontinued due to the adverse event of abdominal discomfort and fatigue, and Subject #4598 decided to become pregnant. The medication was stopped and the subject returned for follow-up visit. The records reviewed included drug accountability, IRB files, sponsor correspondence, inclusion/exclusion criteria, financial disclosure documents, adverse events, and informed consent forms.

The files were well organized and legible. Medical records/source documents were compared to case report form and data listing for primary efficacy endpoints and adverse event reporting. No deficiencies were noted.

The medical records for all subjects were reviewed. The inspection revealed adequate adherence to the regulation and investigational plan. There were no objectionable conditions noted and no Form FDA-483, Inspectional Observations, was issued to Dr. Fung.

The audit did not indicate serious deviations/findings that would impact validity or reliability of the submitted data. The data reported from this site appear acceptable.

CC:

Central Doc. Rm. NDA 208464  
DAVP /Division Director/Debra Birnkrant  
DAVP /Medical Team Leader/Russ Fleischer, PA-C  
DAVP /Project Manager/Patricia Hong Myung -Joo  
DAVP/Medical Officer/Tenvir Bell  
OSI/Office Director/David Burrow  
OSI/DCCE/ Division Director/ Ni Khin  
OSI/DCCE/GCPA/Branch Chief/Kassa Ayalew  
OSI/DCCE/GCPA/Team Leader/Susan Thompson  
OSI/DCCE/GCPA/ Reviewer/ Antoine El Hage  
OSI/ GCP Program Analysts/ Yolanda Patague/ Joseph Peacock  
OSI/Database PM/Dana Walters

{See appended electronic signature page}
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ANTOINE N EL HAGE
08/09/2016

SUSAN D THOMPSON
08/09/2016

KASSA AYALEW
08/10/2016
**LABEL AND LABELING REVIEW**
Division of Medication Error Prevention and Analysis (DMEPA)
Office of Medication Error Prevention and Risk Management (OMEPRM)
Office of Surveillance and Epidemiology (OSE)
Center for Drug Evaluation and Research (CDER)

*** This document contains proprietary information that cannot be released to the public***

<table>
<thead>
<tr>
<th>Date of This Review:</th>
<th>June 21, 2016</th>
</tr>
</thead>
<tbody>
<tr>
<td>Requesting Office or Division:</td>
<td>Division of Antiviral Products (DAVP)</td>
</tr>
<tr>
<td>Application Type and Number:</td>
<td>NDA 208464</td>
</tr>
<tr>
<td>Product Name and Strength:</td>
<td>Vemlidy (tenofovir alafenamide) Tablets 25 mg</td>
</tr>
<tr>
<td>Product Type:</td>
<td>Single Ingredient Product</td>
</tr>
<tr>
<td>Rx or OTC:</td>
<td>Rx</td>
</tr>
<tr>
<td>Applicant/Sponsor Name:</td>
<td>Gilead Sciences, Inc.</td>
</tr>
<tr>
<td>Submission Date:</td>
<td>January 11, 2016</td>
</tr>
<tr>
<td>OSE RCM #:</td>
<td>2016-107</td>
</tr>
<tr>
<td>DMEPA Primary Reviewer:</td>
<td>Mónica Calderón, PharmD, BCPS</td>
</tr>
<tr>
<td>DMEPA Team Leader:</td>
<td>Vicky Borders-Hemphill, PharmD</td>
</tr>
</tbody>
</table>
1 REASON FOR REVIEW
Gilead Sciences, Inc. submitted a new drug application (NDA 208464) for the treatment of chronic hepatitis B in adults. Thus, the Division of Antiviral Products (DAVP) requested DMEPA evaluate the Applicant’s proposed full prescribing information (FPI) and container labels.

2 MATERIALS REVIEWED
We considered the materials listed in Table 1 for this review. The Appendices provide the methods and results for each material reviewed.

<table>
<thead>
<tr>
<th>Material Reviewed</th>
<th>Appendix Section (for Methods and Results)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Information/Prescribing Information</td>
<td>A</td>
</tr>
<tr>
<td>Previous DMEPA Reviews</td>
<td>B (N/A)</td>
</tr>
<tr>
<td>Human Factors Study</td>
<td>C (N/A)</td>
</tr>
<tr>
<td>ISMP Newsletters</td>
<td>D (N/A)</td>
</tr>
<tr>
<td>FDA Adverse Event Reporting System (FAERS)*</td>
<td>E (N/A)</td>
</tr>
<tr>
<td>Other</td>
<td>F (N/A)</td>
</tr>
<tr>
<td>Labels and Labeling</td>
<td>G</td>
</tr>
</tbody>
</table>

N/A=not applicable for this review
*We do not typically search FAERS for label and labeling reviews unless we are aware of medication errors through our routine postmarket safety surveillance

3 OVERALL ASSESSMENT OF THE MATERIALS REVIEWED
Gilead Sciences, Inc. is proposing a single strength 25 mg tablet of Vemlidy. The daily dose is one tablet once daily and the product will be packaged in 30-count bottles, which is supported by the dosage and administration of this product.

DMEPA performed a risk assessment of the proposed container label and FPI and determined the Dosage and Administration section is clear; however, the Vemlidy label will need to be clearly differentiated from the marketed Viread label. We provide recommendations in Section 4.2 to mitigate the risk for wrong drug selection errors and to update the FPI to reflect the conditionally acceptable proprietary name, Vemlidy.

4 CONCLUSION & RECOMMENDATIONS
DMEPA concludes Gilead’s proposed FPI is acceptable. However, to minimize the potential for wrong drug selection errors, we provide recommendations to differentiate the container labels for Vemlidy and Viread in Section 4.2. We also recommend updating the FPI and labels and
labeling with the conditionally acceptable proprietary name, Vemlidy, in Sections 4.1 and 4.2, respectively.

4.1 RECOMMENDATIONS FOR THE DIVISION

Full Prescribing Information

1. Replace “TRADENAME” with the conditionally acceptable proprietary name, Vemlidy.

4.2 RECOMMENDATIONS FOR GILEAD SCIENCES, INC.

We recommend the following be implemented prior to approval of this NDA:

1. As presented, the label for Vemlidy does not have any distinctive characteristics helping to differentiate it from the currently marketed Viread label. Provide a proposal to help differentiate the labels to prevent wrong drug selection errors.
2. Replace “TRADENAME” with the conditionally acceptable proprietary name, Vemlidy.
APPENDIX A. PRODUCT INFORMATION/PRESCRIBING INFORMATION

Table 2 presents relevant product information for Vemlidy that Gilead Sciences, Inc. submitted on January 11, 2016.

<table>
<thead>
<tr>
<th>Table 2. Relevant Product Information for Vemlidy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial Approval Date</td>
</tr>
<tr>
<td>Active Ingredient</td>
</tr>
<tr>
<td>Indication</td>
</tr>
<tr>
<td>Route of Administration</td>
</tr>
<tr>
<td>Dosage Form</td>
</tr>
<tr>
<td>Strength</td>
</tr>
<tr>
<td>Dose and Frequency</td>
</tr>
<tr>
<td>How Supplied</td>
</tr>
<tr>
<td>Storage</td>
</tr>
</tbody>
</table>

1 Page(s) of Draft Labeling have been Withheld in Full as b4 (CCI/TS) immediately following this page
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MONICA M CALDERON
06/21/2016

BRENDA V BORDERS-HEMPHILL
06/22/2016
RPM FILING REVIEW
(Including Memo of Filing Meeting)
To be completed for all new NDAs, BLAs, and Efficacy Supplements [except SE8 (labeling change with clinical data) and SE9 (manufacturing change with clinical data)]

<table>
<thead>
<tr>
<th>Application Information</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDA # 208464</td>
</tr>
<tr>
<td>Original Submission</td>
</tr>
<tr>
<td>NDA Supplement #: S-</td>
</tr>
<tr>
<td>BLA Supplement #: S-</td>
</tr>
<tr>
<td>Efficacy Supplement Category:</td>
</tr>
<tr>
<td>☐ New Indication (SE1)</td>
</tr>
<tr>
<td>☐ New Dosing Regimen (SE2)</td>
</tr>
<tr>
<td>☐ New Route Of Administration (SE3)</td>
</tr>
<tr>
<td>☐ Comparative Efficacy Claim (SE4)</td>
</tr>
<tr>
<td>☐ New Patient Population (SE5)</td>
</tr>
<tr>
<td>☐ Rx To OTC Switch (SE6)</td>
</tr>
<tr>
<td>☐ Accelerated Approval Confirmatory Study (SE7)</td>
</tr>
<tr>
<td>☐ Labeling Change With Clinical Data (SE8)</td>
</tr>
<tr>
<td>☐ Manufacturing Change With Clinical Data (SE9)</td>
</tr>
<tr>
<td>☐ Animal Rule Confirmatory Study (SE10)</td>
</tr>
</tbody>
</table>

Proprietary Name: Vemlidy
Established/Proper Name: tenofovir alafenamide
Dosage Form: Tablet
Strengths: 25 mg

Applicant: Gilead Sciences, Inc.
Agent for Applicant (if applicable): N/A

Date of Application: January 11, 2016
Date of Receipt: January 11, 2016
Date clock started after UN: N/A

PDUFA Goal Date: November 11, 2016
Action Goal Date (if different): 
Filing Date: March 11, 2016
Date of Filing Meeting: March 1, 2016

Chemical Classification (original NDAs only):
☐ Type 1- New Molecular Entity (NME); NME and New Combination
☐ Type 2- New Active Ingredient; New Active Ingredient and New Dosage Form; New Active Ingredient and New Combination
☐ Type 3- New Dosage Form; New Dosage Form and New Combination
☐ Type 4- New Combination
☐ Type 5- New Formulation or New Manufacturer
☐ Type 7- Drug Already Marketed without Approved NDA
☐ Type 8- Partial Rx to OTC Switch

Proposed indication(s)/Proposed change(s): Treatment of hepatitis B virus infection in adults

Type of Original NDA: ☒ 505(b)(1)
AND (if applicable) ☐ 505(b)(2)
Type of NDA Supplement: ☒ 505(b)(1)
☐ 505(b)(2)


Version: 7/10/2015
## Type of BLA
- If 351(k), notify the OND Therapeutic Biologics and Biosimilars Team

### Review Classification:
- The application will be a priority review if:
  - A complete response to a pediatric Written Request (WR) was included (a partial response to a WR that is sufficient to change the labeling should also be a priority review – check with DPMH)
  - The product is a Qualified Infectious Disease Product (QIDP)
  - A Tropical Disease Priority Review Voucher was submitted
  - A Pediatric Rare Disease Priority Review Voucher was submitted

<table>
<thead>
<tr>
<th>Priority</th>
<th>Standard</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pediatric WR</td>
<td>QIDP</td>
</tr>
<tr>
<td>Tropical Disease Priority Review Voucher</td>
<td>Pediatric Rare Disease Priority Review Voucher</td>
</tr>
</tbody>
</table>

### Resubmission after withdrawal? ☐ Resubmission after refuse to file? ☐

### Part 3 Combination Product? ☐
- If yes, contact the Office of Combination Products (OCP) and copy them on all Inter-Center consults

- Convenience kit/Co-package
- Pre-filled drug delivery device/system (syringe, patch, etc.)
- Pre-filled biologic delivery device/system (syringe, patch, etc.)
- Device coated/impregnated/combined with drug
- Device coated/impregnated/combined with biologic
- Separate products requiring cross-labeling
- Drug/Biologic
- Possible combination based on cross-labeling of separate products
- Other (drug/device/biological product)

### Fast Track Designation ☐
- Breakthrough Therapy Designation (set the submission property in DARRTS and notify the CDER Breakthrough Therapy Program Manager) ☐
- Rolling Review ☐
- Orphan Designation ☐

### Rx-to-OTC switch, Full ☐
- Rx-to-OTC switch, Partial ☐
- Direct-to-OTC ☐

### PMC response
- PMR response:
  - FDAAA [505(o)] ☐
  - PREA deferred pediatric studies (FDCA Section 505B) ☐
  - Accelerated approval confirmatory studies (21 CFR 314.510/21 CFR 601.41)
  - Animal rule postmarketing studies to verify clinical benefit and safety (21 CFR 314.610/21 CFR 601.42)

### Collaborative Review Division (if OTC product):
- List referenced IND Number(s):
  - IND (b) (4), IND 52849, and NDA 21356 for Viread (tenofovir disoproxil fumarate (TDF))
  - IND 63737 and NDA 207561 for TAF (tenofovir alafenamide)
  - IND 101283 and NDA 203094 for cobicistat
  - IND 103093, IND 111077 and NDA 203100 for Stribild (E/C/F/TDF)
  - IND 106739, IND 118605 and NDA 204671 for Sovaldi (sofosbuvir)
  - IND 111851 and NDA 203093 for Descovy (F/TAF)
  - IND 115561 for TAF
  - IND 115670 for velpatasvir
  - IND 118605 and NDA 208341 for sofosbuvir/velpatasvir
  - NDA 203093 for elvitegravir
<table>
<thead>
<tr>
<th>Goal Dates/Product Names/Classification Properties</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>PDUFA/BsUFA and Action Goal dates correct in tracking system?</td>
<td>❌</td>
<td>☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, ask the document room staff to correct them immediately. These are the dates used for calculating inspection dates.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are the established/proper and applicant names correct in tracking system?</td>
<td>❌</td>
<td>☐</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, ask the document room staff to make the corrections. Also, ask the document room staff to add the established/proper name to the supporting IND(s) if not already entered into tracking system.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the review priority (S or P) and all appropriate classifications/properties entered into tracking system (e.g., chemical classification, combination product classification, orphan drug)? Check the New Application and New Supplement Notification Checklists for a list of all classifications/properties at: <a href="http://inside.fda.gov:9003/CDER/OfficeofBusinessProcessSupport/ucm163969.htm">http://inside.fda.gov:9003/CDER/OfficeofBusinessProcessSupport/ucm163969.htm</a></td>
<td>❌</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td>If no, ask the document room staff to make the appropriate entries.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Application Integrity Policy</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is the application affected by the Application Integrity Policy (AIP)? Check the AIP list at: <a href="http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm">http://www.fda.gov/ICECI/EnforcementActions/ApplicationIntegrityPolicy/default.htm</a></td>
<td>☐</td>
<td>YES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, explain in comment column.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If affected by AIP, has OC been notified of the submission? If yes, date notified:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>User Fees</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is Form 3397 (User Fee Cover Sheet)/Form 3792 (Biosimilar User Fee Cover Sheet) included with authorized signature?</td>
<td>❌</td>
<td>☐</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### User Fee Status

If a user fee is required and it has not been paid (and it is not exempted or waived), the application is unacceptable for filing following a 5-day grace period. Review stops. Send Unacceptable for Filing (UN) letter and contact user fee staff.

**Payment for this application (check daily email from UserFeeAR@fda.hhs.gov):**

- [ ] Paid
- [ ] Exempt (orphan, government)
- [ ] Waived (e.g., small business, public health)
- [ ] Not required

If the firm is in arrears for other fees (regardless of whether a user fee has been paid for this application), the application is unacceptable for filing (5-day grace period does not apply). Review stops. Send UN letter and contact the user fee staff.

**Payment of other user fees:**

- [ ] Not in arrears
- [ ] In arrears

### User Fee Bundling Policy


Has the user fee bundling policy been appropriately applied? If no, or you are not sure, consult the User Fee Staff.

- [ ] Yes
- [ ] No

### 505(b)(2) (NDAs/NDA Efficacy Supplements only)

**Is the application a 505(b)(2) NDA? (Check the 356h form, cover letter, and annotated labeling). If yes, answer the bulleted questions below:**

- [ ] Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA?

- [ ] Is the application for a duplicate of a listed drug whose only difference is that the extent to which the active ingredient(s) is absorbed or otherwise made available to the site of action is less than that of the reference listed drug (RLD)? [see 21 CFR 314.54(b)(1)].

- [ ] Is the application for a duplicate of a listed drug whose only difference is that the rate at which the proposed product’s active ingredient(s) is absorbed or made available to the site of action is unintentionally less than that of the listed drug [see 21 CFR 314.54(b)(2)]?

If you answered yes to any of the above bulleted questions, the application may be refused for filing under 21 CFR 314.101(d)(9). Contact the 505(b)(2) review staff in the Immediate Office of New Drugs for advice.

- [ ] Is there unexpired exclusivity on another listed drug product containing the same active moiety (e.g., 5-year, 3-year, orphan, or pediatric exclusivity)?


If yes, please list below:
<table>
<thead>
<tr>
<th>Application No.</th>
<th>Drug Name</th>
<th>Exclusivity Code</th>
<th>Exclusivity Expiration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

If there is unexpired, 5-year exclusivity remaining on another listed drug product containing the same active moiety, a 505(b)(2) application cannot be submitted until the period of exclusivity expires (unless the applicant provides paragraph IV patent certification; then an application can be submitted four years after the date of approval.) Pediatric exclusivity will extend both of the timeframes in this provision by 6 months. 21 CFR 314.108(b)(2).

Unexpired, 3-year exclusivity may block the approval but not the submission of a 505(b)(2) application.

<table>
<thead>
<tr>
<th>Exclusivity</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Does another product (same active moiety) have orphan exclusivity for the same indication? Check the Orphan Drug Designations and Approvals list at: <a href="http://www.accessdata.fda.gov/scripts/opa/listing/arduino/index.cfm">http://www.accessdata.fda.gov/scripts/opa/listing/arduino/index.cfm</a></td>
<td>☐</td>
<td>☑</td>
<td></td>
<td>Viread (tenofovir disoproxil fumarate) was approved for orphan designation on March 17, 2009 for treatment of pediatric HIV infection.</td>
</tr>
</tbody>
</table>

If another product has orphan exclusivity, is the product considered to be the same product according to the orphan drug definition of sameness [see 21 CFR 316.3(b)(13)]? ☐ ☑ ☐

If yes, consult the Director, Division of Regulatory Policy II, Office of Regulatory Policy.

NDAs/NDA efficacy supplements only: Has the applicant requested 5-year or 3-year Waxman-Hatch exclusivity? ☑ ☐ ☐

If yes, # years requested: 3 years

Note: An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.

NDAs only: Is the proposed product a single enantiomer of a racemic drug previously approved for a different therapeutic use? ☐ ☑ ☐

If yes, did the applicant: (a) elect to have the single enantiomer (contained as an active ingredient) not be considered the same active ingredient as that contained in an already approved racemic drug, and/or (b): request exclusivity pursuant to section 505(m) of the Act (per FDAAA Section 1113)? ☐ ☑ ☐

If yes, contact the Orange Book Staff (CDER-Orange Book Staff).

BLAs only: Has the applicant requested 12-year exclusivity under section 351(k)(7) of the PHS Act? ☐ ☐ ☐

Version: 7/10/2015

Reference ID: 3895831
If yes, notify Marlene Schultz-DePalo, CDER Purple Book Manager

*Note:* Exclusivity requests may be made for an original BLA submitted under Section 351(a) of the PHS Act (i.e., a biological reference product). A request may be located in Module 1.3.5.3 and/or other sections of the BLA and may be included in a supplement (or other correspondence) if exclusivity has not been previously requested in the original 351(a) BLA. An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.

### Format and Content

- Do not check mixed submission if the only electronic component is the content of labeling (COL).

- □ All paper (except for COL)
- □ All electronic
- □ Mixed (paper/electronic)
- □ CTD
- □ Non-CTD
- □ Mixed (CTD/non-CTD)

### Overall Format/Content

<table>
<thead>
<tr>
<th></th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If electronic submission, does it follow the eCTD guidance?¹</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If not, explain (e.g., waiver granted).</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Index: Does the submission contain an accurate comprehensive index?</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the submission complete as required under 21 CFR 314.50 (<em>NDAs/NDA efficacy supplements</em>) or under 21 CFR 601.2 (<em>BLAs/BLA efficacy supplements</em>) including:</td>
<td>✗</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ legible</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ English (or translated into English)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ pagination</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>□ navigable hyperlinks (electronic submissions only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, explain.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BLAs only: Companion application received if a shared or divided manufacturing arrangement?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, BLA #</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Forms and Certifications

*Electronic* forms and certifications with electronic signatures (scanned, digital, or electronic – similar to DARRTS, e.g., /s/) are acceptable. *Otherwise, paper* forms and certifications with hand-written signatures must be included. *Forms* include: user fee cover sheet (3397/3792), application form (356h), patent information (3542a), financial disclosure (3454/3455), and clinical trials (3674); *Certifications* include: debarment certification, patent certification(s), field copy certification, and pediatric certification.

<table>
<thead>
<tr>
<th>Application Form</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is form FDA 356h included with authorized signature per 21 CFR 314.50(a)?</td>
<td>✗</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td><em>If foreign applicant, a U.S. agent must sign the form [see 21 CFR 314.50(a)(5)].</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Are all establishments and their registration numbers listed on the form/attached to the form?</td>
<td>✗</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patent Information (NDAs/NDA efficacy supplements only)</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is patent information submitted on form FDA 3542a per 21 CFR 314.53(c)?</td>
<td>✗</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Financial Disclosure</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Are financial disclosure forms FDA 3454 and/or 3455 included with authorized signature per 21 CFR 54.4(a)(1) and (3)?</td>
<td>✗</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td><em>Forms must be signed by the APPLICANT, not an Agent [see 21 CFR 54.2(g)].</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>Note: Financial disclosure is required for bioequivalence studies that are the basis for approval.</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Clinical Trials Database</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is form FDA 3674 included with authorized signature?</td>
<td>✗</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td><em>If yes, ensure that the application is also coded with the supporting document category, “Form 3674.”</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><em>If no, ensure that language requesting submission of the form is included in the acknowledgement letter sent to the applicant</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Debarment Certification</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Is a correctly worded Debarment Certification included with authorized signature?</td>
<td>✗</td>
<td>☐</td>
<td>☐</td>
<td></td>
</tr>
<tr>
<td><em>Certification is not required for supplements if submitted in the original application: If foreign applicant, both the applicant and the U.S. Agent must sign the certification [per Guidance for Industry: Submitting Debarment Certifications].</em></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| *Note: Debarment Certification should use wording in FD&C Act Section 306(k)(1) i.e., “[Name of applicant] hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.”* Applicant may not use wording such as, “To the best of my
### Field Copy Certification (NDAs/NDA efficacy supplements only)

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For paper submissions only:* Is a Field Copy Certification (that it is a true copy of the CMC technical section) included?

*Field Copy Certification is not needed if there is no CMC technical section or if this is an electronic submission (the Field Office has access to the EDR)*

*If maroon field copy jackets from foreign applicants are received, return them to CDR for delivery to the appropriate field office.*

### Controlled Substance/Product with Abuse Potential

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*For NMEs:*

Is an Abuse Liability Assessment, including a proposal for scheduling, submitted per 21 CFR 314.50(d)(5)(vii)?

*If yes, date consult sent to the Controlled Substance Staff:*

---

### Pediatrics

<table>
<thead>
<tr>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*PREA*

Does the application trigger PREA?

*If yes, notify PeRC@fda.hhs.gov to schedule required PeRC meeting*2

*Note: NDAs/BLAs/efficacy supplements for new active ingredients (including new fixed combinations), new indications, new dosage forms, new dosing regimens, or new routes of administration trigger PREA. All waiver & deferral requests, pediatric plans, and pediatric assessment studies must be reviewed by PeRC prior to approval of the application/supplement.*

*If the application triggers PREA, is there an agreed Initial Pediatric Study Plan (IPSP)?*

*If no, may be an RTF issue - contact DPMH for advice.*

---

2 [http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/PediatricandMaternalHealthStaff/ucm027829.htm](http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/PediatricandMaternalHealthStaff/ucm027829.htm)

Reference ID: 3895831
<table>
<thead>
<tr>
<th>Question</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>If required by the agreed iPSP, are the pediatric studies outlined in the agreed iPSP completed and included in the application?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, may be an RTF issue - contact DPMH for advice.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>BPCA:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is this submission a complete response to a pediatric Written Request?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, notify Pediatric Exclusivity Board RPM (pediatric exclusivity determination is required)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Proprietary Name</strong></td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is a proposed proprietary name submitted?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, ensure that the application is also coded with the supporting document category, “Proprietary Name/Request for Review.”</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>REMS</strong></td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is a REMS submitted?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If yes, send consult to OSE/DRISK and notify OC/OSI/DSC/PMSB via the CDER OSI RMP mailbox</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prescription Labeling</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Check all types of labeling submitted.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Package Insert (PI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Patient Package Insert (PPI)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Instructions for Use (IFU)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Medication Guide (MedGuide)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Carton labels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Immediate container labels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Diluent</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Other (specify)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Electronic Content of Labeling (COL)</strong></td>
<td>YES</td>
<td>NO</td>
<td>NA</td>
<td>Comment</td>
</tr>
<tr>
<td>Is submitted in SPL format?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If no, request applicant to submit SPL before the filing date.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Is the PI submitted in PLR format?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If PI not submitted in PLR format, was a waiver or deferral requested before the application was received or in the submission?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>If requested before application was submitted, what is the status of the request?</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

3 [http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/PediatricandMaternalHealthStaff/ucm027837.htm](http://inside.fda.gov:9003/CDER/OfficeofNewDrugs/ImmediateOffice/PediatricandMaternalHealthStaff/ucm027837.htm)

If no waiver or deferral, request applicant to submit labeling in PLLR format before the filing date.

For applications submitted on or after June 30, 2015:
Is the PI submitted in PLLR format?[^5]

Has a review of the available pregnancy and lactation data been included?

For applications submitted on or after June 30, 2015:
If PI not submitted in PLLR format, was a waiver or deferral requested before the application was received or in the submission? If requested before application was submitted, what is the status of the request?

If no waiver or deferral, request applicant to submit labeling in PLLR/PLLR format before the filing date.

All labeling (PI, PPI, MedGuide, IFU, carton and immediate container labels) consulted to OPDP?

MedGuide, PPI, IFU (plus PI) consulted to OSE/DRISK? (send WORD version if available)

Carton and immediate container labels, PI, PPI sent to OSE/DMEPA and appropriate CMC review office in OPQ (OBP or ONDP)?

OTC Labeling
Check all types of labeling submitted.

- Outer carton label
- Immediate container label
- Blister card
- Blister backing label
- Consumer Information Leaflet (CIL)
- Physician sample
- Consumer sample
- Other (specify)

Is electronic content of labeling (COL) submitted?

If no, request in 74-day letter.

Are annotated specifications submitted for all stock keeping units (SKUs)?

If no, request in 74-day letter.

If representative labeling is submitted, are all represented SKUs defined?

If no, request in 74-day letter.

All labeling/packaging sent to OSE/DMEPA?


Version: 7/10/2015

Reference ID: 3895831
### Other Consults

<table>
<thead>
<tr>
<th>Are additional consults needed? (e.g., IFU to CDRH; QT study report to QT Interdisciplinary Review Team)</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
</table>
| | | | | • DBRUP - 2/12/16  
• DCRP - 2/12/16 |

**If yes, specify consult(s) and date(s) sent:**

### Meeting Minutes/SPAs

<table>
<thead>
<tr>
<th>End-of Phase 2 meeting(s)? Date(s): June 17, 2013</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-NDA Meeting scheduled under IND 115561; however, Gilead cancelled after receiving FDA’s preliminary comments sent on 6/16/15</td>
</tr>
</tbody>
</table>

**If yes, distribute minutes before filing meeting**

<table>
<thead>
<tr>
<th>Pre-NDA/Pre-BLA/Pre-Supplement meeting(s)? Date(s): June 18, 2015</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pre-NDA Meeting scheduled under IND 115561; however, Gilead cancelled after receiving FDA’s preliminary comments sent on 6/16/15</td>
</tr>
</tbody>
</table>

**If yes, distribute minutes before filing meeting**

<table>
<thead>
<tr>
<th>Any Special Protocol Assessments (SPAs)? Date(s):</th>
<th>YES</th>
<th>NO</th>
<th>NA</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**If yes, distribute letter and/or relevant minutes before filing meeting**

### MEMO OF FILING MEETING

**DATE:** March 1, 2016

**BACKGROUND:**

Tenofovir (TFV) is a nucleotide analog with limited oral bioavailability that inhibits HBV and HIV-1 reverse transcription. TDF was first approved for the treatment of HIV-1 infection in 2001 to be given in combination with other antiretroviral (ARV) agents and was first approved for treatment of chronic hepatitis B (CHB) as monotherapy in 2008. TDF is the preferred treatment for CHB in all major treatment guidelines.

Tenofovir alafenamide (TAF) is a phosphonoamidate prodrug of TFV. TAF is more stable in plasma than TDF, resulting in higher intracellular levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP) to target cells. The distinct metabolism of TAF offers the potential for an improved safety profile when compared with TDF. TAF addresses some of the limitations of currently available therapies. TAF provides a potent, highly effective therapy with a low potential for resistance development.

The two Phase 3 studies (Studies GS-US-320-0108 and GS-US-320-0110) in subjects with CHB were conducted to study the efficacy and safety of TAF 25 mg. Both Phase 3 studies have achieved their primary endpoints, which form the basis for this marketing application.
# REVIEW TEAM:

<table>
<thead>
<tr>
<th>Discipline/Organization</th>
<th>Names</th>
<th>Present at filing meeting? (Y or N)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regulatory Project Management</td>
<td>RPM: Myung-Joo Patricia Hong</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>CPMS/TL: Beth Thompson</td>
<td>Y</td>
</tr>
<tr>
<td>Cross-Discipline Team Leader (CDTL)</td>
<td>Russ Fleischer</td>
<td>Y</td>
</tr>
<tr>
<td>Division Director/Deputy</td>
<td>Debra Birnkrant/Jeff Murray</td>
<td>Y</td>
</tr>
<tr>
<td>Office Director/Deputy</td>
<td>N/A</td>
<td></td>
</tr>
<tr>
<td>Clinical</td>
<td>Reviewer: Tanvir Bell</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>TL: Russ Fleischer</td>
<td></td>
</tr>
<tr>
<td>Social Scientist Review (for OTC products)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TL: N/A</td>
<td></td>
</tr>
<tr>
<td>OTC Labeling Review (for OTC products)</td>
<td>Reviewer: N/A</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TL: N/A</td>
<td></td>
</tr>
<tr>
<td>Clinical Microbiology (for antimicrobial products)</td>
<td>Reviewer: Sung Rhee</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>TL: Jules O’Rear</td>
<td>Y</td>
</tr>
<tr>
<td>Clinical Pharmacology</td>
<td>Reviewer: Mario Sampson</td>
<td>N</td>
</tr>
<tr>
<td></td>
<td>TL: Islam Younis</td>
<td>Y</td>
</tr>
<tr>
<td>Genomics</td>
<td>Reviewer: None</td>
<td></td>
</tr>
<tr>
<td>Pharmacometrics</td>
<td>Reviewer: None</td>
<td></td>
</tr>
<tr>
<td>Biostatistics</td>
<td>Reviewer: Frazer Smith</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>TL: Tamban Vallapal</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>Greg Soon</td>
<td></td>
</tr>
<tr>
<td>Nonclinical (Pharmacology/Toxicology)</td>
<td>Reviewer: Claudia Wrzesinski</td>
<td>Y</td>
</tr>
<tr>
<td></td>
<td>TL: Hanan Ghantous</td>
<td>Y</td>
</tr>
<tr>
<td>Statistics (carcinogenicity)</td>
<td>Reviewer: None</td>
<td></td>
</tr>
<tr>
<td></td>
<td>TL: None</td>
<td></td>
</tr>
<tr>
<td>Product Quality (CMC) Review Team:</td>
<td>ATL:</td>
<td>Stephen Miller</td>
</tr>
<tr>
<td>---------------------------------------------------</td>
<td>--------</td>
<td>----------------</td>
</tr>
<tr>
<td>RBPM:</td>
<td>Florence Aisida</td>
<td>Y</td>
</tr>
</tbody>
</table>

- **Drug Substance**
  - Reviewer: None

- **Drug Product**
  - Reviewer: Yong Wang | Y |

- **Process**
  - Reviewer: Ying Wang | N |

- **Microbiology**
  - Reviewer: None | N |

- **Facility**
  - Reviewer: Frank Wackes | N |

- **Biopharmaceutics**
  - Reviewer: Jing Li | N |

- **Immunogenicity**
  - Reviewer: None |

- **Labeling (BLAs only)**
  - Reviewer: N/A |

- **Other (e.g., Branch Chiefs, EA Reviewer)**
  - None |

<table>
<thead>
<tr>
<th>OMP/OMPI/DMPP (Patient labeling: MG, PPI, IFU)</th>
<th>Reviewer: Medina Rowe</th>
<th>Y</th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td>Barbara Fuller</td>
<td>N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OMP/OPDP (PI, PPI, MedGuide, IFU, carton and immediate container labels)</th>
<th>Reviewer: Kemi Asante</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OSE/DMEPA (proprietary name, carton/container labels)</th>
<th>Reviewer: Monica Calderon</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td>Vicky Borders-Hemphill</td>
<td>N</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OSE/DRISK (REMS)</th>
<th>Reviewer:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>OC/OSI/DSC/PMSB (REMS)</th>
<th>Reviewer:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bioresearch Monitoring (OSI)</th>
<th>Reviewer: Tony El-Hage</th>
<th>N</th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Controlled Substance Staff (CSS)</th>
<th>Reviewer:</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>TL:</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Other reviewers/disciplines**

<table>
<thead>
<tr>
<th>Labeling</th>
<th>ADL</th>
<th>Stacey Min</th>
<th>Y</th>
</tr>
</thead>
</table>
# FILING MEETING DISCUSSION:

| GENERAL | 
| --- | --- |
| • 505(b)(2) filing issues: | Not Applicable |
|   o Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA? | YES NO |
|   o Did the applicant provide a scientific “bridge” demonstrating the relationship between the proposed product and the referenced product(s)/published literature? | YES NO |
| Describe the scientific bridge (e.g., information to demonstrate sufficient similarity between the proposed product and the listed drug(s) such as BA/BE studies or to justify reliance on information described in published literature): | |
| • Per reviewers, are all parts in English or English translation? | YES NO |
|   If no, explain: | |
| • Electronic Submission comments | Not Applicable |
|   List comments: | No comments |

| CLINICAL | 
| --- | --- |
| Comments: | FILE |
| • Clinical study site(s) inspections(s) needed? | YES - 4 clinical sites are selected |
|   If no, explain: | NO |

If no, for an NME NDA or original BLA, include the reason. For example:
- this drug/biologic is not the first in its class
- the clinical study design was acceptable
- the application did not raise significant safety or efficacy issues
- the application did not raise significant public health questions on the role of the drug/biologic in the diagnosis, cure, mitigation, treatment or prevention of a disease

If the application is affected by the AIP, has the division made a recommendation regarding whether or not an exception to the AIP should be granted to permit review based on medical necessity or public health significance?

Comments:

<table>
<thead>
<tr>
<th>CONTROLLED SUBSTANCE STAFF</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>• Abuse Liability/Potential</td>
<td></td>
</tr>
</tbody>
</table>

Comments:

<table>
<thead>
<tr>
<th>CLINICAL MICROBIOLOGY</th>
<th></th>
</tr>
</thead>
</table>

Comments:

<table>
<thead>
<tr>
<th>CLINICAL PHARMACOLOGY</th>
<th></th>
</tr>
</thead>
</table>

Comments:

- Clinical pharmacology study site(s) inspections(s) needed?

<table>
<thead>
<tr>
<th>BIOSTATISTICS</th>
<th></th>
</tr>
</thead>
</table>

Comments:

<table>
<thead>
<tr>
<th>NONCLINICAL (PHARMACOLOGY/TOXICOLOGY)</th>
<th></th>
</tr>
</thead>
</table>

Comments:

<table>
<thead>
<tr>
<th>PRODUCT QUALITY (CMC)</th>
<th></th>
</tr>
</thead>
</table>

Version: 7/10/2015

Reference ID: 3895831
<table>
<thead>
<tr>
<th>Comments:</th>
<th>☐ Review issues for 74-day letter</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>New Molecular Entity (NDAs only)</strong></td>
<td></td>
</tr>
<tr>
<td>• Is the product an NME?</td>
<td>☐ YES ☒ NO</td>
</tr>
<tr>
<td><strong>Environmental Assessment</strong></td>
<td></td>
</tr>
<tr>
<td>• Categorical exclusion for environmental assessment (EA) requested?</td>
<td>☒ YES ☐ NO</td>
</tr>
<tr>
<td><strong>If no,</strong> was a complete EA submitted?</td>
<td>☐ YES ☒ NO</td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
</tr>
<tr>
<td><strong>Facility Inspection</strong></td>
<td></td>
</tr>
<tr>
<td>• Establishment(s) ready for inspection?</td>
<td>☒ YES ☐ NO</td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
</tr>
<tr>
<td><strong>Facility/Microbiology Review (BLAs only)</strong></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td>☒ Not Applicable</td>
</tr>
<tr>
<td><strong>CMC Labeling Review (BLAs only)</strong></td>
<td></td>
</tr>
<tr>
<td>Comments:</td>
<td></td>
</tr>
<tr>
<td><strong>APPLICATIONS IN THE PROGRAM (PDUFA V) (NME NDAs/Original BLAs)</strong></td>
<td></td>
</tr>
<tr>
<td>• Were there agreements made at the application’s pre-submission meeting (and documented in the minutes) regarding certain late submission components that could be submitted within 30 days after receipt of the original application?</td>
<td>☒ N/A</td>
</tr>
<tr>
<td>• If so, were the late submission components all submitted within 30 days?</td>
<td>☐ YES ☒ NO</td>
</tr>
</tbody>
</table>

Reference ID: 3895831
- What late submission components, if any, arrived after 30 days?

- Was the application otherwise complete upon submission, including those applications where there were no agreements regarding late submission components?
  - YES
  - NO

- Is a comprehensive and readily located list of all clinical sites included or referenced in the application?
  - YES
  - NO

- Is a comprehensive and readily located list of all manufacturing facilities included or referenced in the application?
  - YES
  - NO

REGULATORY PROJECT MANAGEMENT

Signatory Authority: Debra Birnkrant, M.D.

Date of Mid-Cycle Meeting (for NME NDAs/BLAs in “the Program” PDUFA V):

21st Century Review Milestones (see attached) (listing review milestones in this document is optional):

Comments:

REGULATORY CONCLUSIONS/DEFICIENCIES

- The application is unsuitable for filing. Explain why:

- The application, on its face, appears to be suitable for filing.

  Review Issues:
  - No review issues have been identified for the 74-day letter.
  - Review issues have been identified for the 74-day letter.

Review Classification:
  - Standard Review
  - Priority Review
<table>
<thead>
<tr>
<th>Action Item</th>
</tr>
</thead>
<tbody>
<tr>
<td>✗ Ensure that any updates to the review priority (S or P) and classifications/properties are entered into the electronic archive (e.g., chemical classification, combination product classification, orphan drug).</td>
</tr>
<tr>
<td>☐ If RTF, notify everyone who already received a consult request, OSE PM, and RBPM</td>
</tr>
<tr>
<td>☐ If filed, and the application is under AIP, prepare a letter either granting (for signature by Center Director) or denying (for signature by ODE Director) an exception for review.</td>
</tr>
<tr>
<td>☐ If priority review, notify applicant in writing by day 60 (see CST for choices)</td>
</tr>
<tr>
<td>✗ Send review issues/no review issues by day 74</td>
</tr>
<tr>
<td>✗ Conduct a PLR format labeling review and include labeling issues in the 74-day letter</td>
</tr>
<tr>
<td>☐ Update the PDUTA V DARRTS page (for applications in the Program)</td>
</tr>
<tr>
<td>☐ Other</td>
</tr>
</tbody>
</table>

Annual review of template by OND ADRAs completed: September 2014
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MYUNG JOO P HONG
03/02/2016

ELIZABETH G THOMPSON
03/02/2016
REGULATORY PROJECT MANAGER
PHYSICIAN LABELING RULE (PLR) FORMAT REVIEW
OF THE PRESCRIBING INFORMATION

Complete for all new NDAs, BLAs, Efficacy Supplements, and PLR Conversion Labeling Supplements

Application: NDA 208464
Application Type: New NDA
Drug Name(s)/Dosage Form(s): tenofovir alafenamide (TAF), 25 mg tablet
Applicant: Gilead Sciences, Inc.
Receipt Date: January 11, 2016
Goal Date: November 11, 2016

1. Regulatory History and Applicant’s Main Proposals

Tenofovir (TFV) is a nucleotide analog with limited oral bioavailability that inhibits HBV and HIV-1 reverse transcription. Tenofovir diphosphate (TDF) was first approved for the treatment of HIV-1 infection in 2001 to be given in combination with other antiretroviral (ARV) agents and was first approved for treatment of chronic hepatitis B (CHB) as monotherapy in 2008. TDF is the preferred treatment for CHB in all major treatment guidelines.

Tenofovir alafenamide (TAF) is a phosphonoamidate prodrug of TFV. TAF is more stable in plasma than TDF, resulting in higher intracellular levels of the active phosphorylated metabolite tenofovir diphosphate (TFV-DP) to target cells. The distinct metabolism of TAF offers the potential for an improved safety profile when compared with TDF. TAF addresses some of the limitations of currently available therapies. TAF provides a potent, highly effective therapy with a low potential for resistance development.

The two Phase 3 studies (Studies GS-US-320-0108 and GS-US-320-0110) in subjects with CHB were conducted to study the efficacy and safety of TAF 25 mg. Both Phase 3 studies have achieved their primary endpoints, which form the basis for this marketing application.

2. Review of the Prescribing Information

This review is based on the applicant’s submitted Word format of the prescribing information (PI). The applicant’s proposed PI was reviewed in accordance with the labeling format requirements listed in the “Selected Requirements of Prescribing Information (SRPI)” checklist (see Section 4 of this review).

3. Conclusions/Recommendations

No SRPI format deficiencies were identified in the review of this PI.

Reference ID: 3880330
4. Selected Requirements of Prescribing Information

The Selected Requirement of Prescribing Information (SRPI) is a 41-item, drop-down checklist of important format elements of the prescribing information (PI) based on labeling regulations (21 CFR 201.56 and 201.57) and guidances.

Highlights

See Appendix for a sample tool illustrating Highlights format.

HIGHLIGHTS GENERAL FORMAT

YES 1. Highlights (HL) must be in a minimum of 8-point font and should be in two-column format, with ½ inch margins on all sides and between columns.

Comment:

YES 2. The length of HL must be one-half page or less unless a waiver has been granted in a previous submission. The HL Boxed Warning does not count against the one-half page requirement. Instructions to complete this item: If the length of the HL is one-half page or less, select “YES” in the drop-down menu because this item meets the requirement. However, if HL is longer than one-half page, select “NO” unless a waiver has been granted.

Comment:

YES 3. A horizontal line must separate:
- HL from the Table of Contents (TOC), and
- TOC from the Full Prescribing Information (FPI).

Comment:

YES 4. All headings in HL (from Recent Major Changes to Use in Specific Populations) must be bolded and presented in the center of a horizontal line. (Each horizontal line should extend over the entire width of the column.) The HL headings (from Recent Major Changes to Use in Specific Populations) should be in UPPER CASE letters. See Appendix for HL format.

Comment:

YES 5. White space should be present before each major heading in HL. There must be no white space between the HL Heading and HL Limitation Statement. There must be no white space between the product title and Initial U.S. Approval. See Appendix for HL format.

Comment:

YES 6. Each summarized statement or topic in HL must reference the section(s) or subsection(s) of the Full Prescribing Information (FPI) that contain more detailed information. The preferred format is the numerical identifier in parenthesis [e.g., (1.1)] at the end of each summarized statement or topic.

Comment:

YES 7. Headings in HL must be presented in the following order:

<table>
<thead>
<tr>
<th>Heading</th>
<th>Required/Optional</th>
</tr>
</thead>
<tbody>
<tr>
<td>Highlights Heading</td>
<td>Required</td>
</tr>
<tr>
<td>Highlights Limitation Statement</td>
<td>Required</td>
</tr>
<tr>
<td>Product Title</td>
<td>Required</td>
</tr>
</tbody>
</table>
### Selected Requirements of Prescribing Information

<table>
<thead>
<tr>
<th>Requirement</th>
<th>Requirement Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial U.S. Approval</td>
<td>Required</td>
</tr>
<tr>
<td>Boxed Warning</td>
<td>Required if a BOXED WARNING is in the FPI</td>
</tr>
<tr>
<td>Recent Major Changes</td>
<td>Required for only certain changes to PI*</td>
</tr>
<tr>
<td>Indications and Usage</td>
<td>Required</td>
</tr>
<tr>
<td>Dosage and Administration</td>
<td>Required</td>
</tr>
<tr>
<td>Dosage Forms and Strengths</td>
<td>Required</td>
</tr>
<tr>
<td>Contraindications</td>
<td>Required (if no contraindications must state “None.”)</td>
</tr>
<tr>
<td>Warnings and Precautions</td>
<td>Not required by regulation, but should be present</td>
</tr>
<tr>
<td>Adverse Reactions</td>
<td>Required</td>
</tr>
<tr>
<td>Drug Interactions</td>
<td>Optional</td>
</tr>
<tr>
<td>Use in Specific Populations</td>
<td>Optional</td>
</tr>
<tr>
<td>Patient Counseling Information Statement</td>
<td>Required</td>
</tr>
<tr>
<td>Revision Date</td>
<td>Required</td>
</tr>
</tbody>
</table>

* RMC only applies to five labeling sections in the FPI: BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS.

**Comment:**

### HIGHLIGHTS DETAILS

#### Highlights Heading

**YES** 8. At the beginning of HL, the following heading, “HIGHLIGHTS OF PRESCRIBING INFORMATION” must be **bolded** and should appear in all UPPER CASE letters.

**Comment:**

#### Highlights Limitation Statement

**YES** 9. The **bolded** HL Limitation Statement must include the following verbatim statement: “These highlights do not include all the information needed to use (insert NAME OF DRUG PRODUCT) safely and effectively. See full prescribing information for (insert NAME OF DRUG PRODUCT).” The name of drug product should appear in UPPER CASE letters.

**Comment:**

#### Product Title in Highlights

**YES** 10. Product title must be **bolded**.

**Comment:**

#### Initial U.S. Approval in Highlights

**YES** 11. Initial U.S. Approval must be **bolded**, and include the verbatim statement “Initial U.S. Approval:” followed by the 4-digit year.

**Comment:**

#### Boxed Warning (BW) in Highlights

**YES** 12. All text in the BW must be **bolded**.

**Comment:**

**YES** 13. The BW must have a title in UPPER CASE, following the word **“WARNING”** and other words to identify the subject of the warning. Even if there is more than one warning, the term **“WARNING”** and not **“WARNINGS”** should be used. For example: **“WARNING: SERIOUS INFECTIONS and ACUTE HEPATIC FAILURE”**. If there is more than one warning in the
Selected Requirements of Prescribing Information

BW title, the word “and” in lower case can separate the warnings. The BW title should be centered.

**Comment:**

YES 14. The BW must always have the verbatim statement “*See full prescribing information for complete boxed warning.*” This statement must be placed immediately beneath the BW title, and should be centered and appear in italics.

**Comment:**

YES 15. The BW must be limited in length to 20 lines. (This includes white space but does not include the BW title and the statement “*See full prescribing information for complete boxed warning.*”)

**Comment:**

Recent Major Changes (RMC) in Highlights

N/A 16. RMC pertains to only five sections of the FPI: BOXED WARNING, INDICATIONS AND USAGE, DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS AND PRECAUTIONS. Labeling sections for RMC must be listed in the same order in HL as they appear in the FPI.

**Comment:** Original NDA submission.

N/A 17. The RMC must include the section heading(s) and, if appropriate, subsection heading(s) affected by the recent major change, together with each section’s identifying number and date (month/year format) on which the change was incorporated in the PI (supplement approval date). For example, “Warnings and Precautions, Acute Liver Failure (5.1) --- 8/2015.”

**Comment:**

N/A 18. A changed section must be listed under the RMC heading for at least one year after the date of the labeling change and must be removed at the first printing subsequent to the one year period. (No listing should be one year older than the revision date.)

**Comment:**

Dosage Forms and Strengths in Highlights

YES 19. For a product that has more than one dosage form (e.g., capsules, tablets, injection), bulleted headings should be used.

**Comment:** Only tablet form

Contraindications in Highlights

YES 20. All contraindications listed in the FPI must also be listed in HL. If there is more than one contraindication, each contraindication should be bulleted. If no contraindications are known, must include the word “None.”

**Comment:**

Adverse Reactions in Highlights
Selected Requirements of Prescribing Information

21. For drug products other than vaccines, the verbatim **bolded** statement must be present: “To report SUSPECTED ADVERSE REACTIONS, contact (insert name of manufacturer) at (insert manufacturer’s U.S. phone number which should be a toll-free number) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.”

*Comment:*

**Patient Counseling Information Statement in Highlights**

22. The Patient Counseling Information statement must include one of the following three **bolded** verbatim statements that is most applicable:

- If a product does not have FDA-approved patient labeling:
  - See 17 for PATIENT COUNSELING INFORMATION

- If a product has (or will have) FDA-approved patient labeling:
  - See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling
  - See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

*Comment: “See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling” proposed.*

**Revision Date in Highlights**

23. The revision date must be at the end of HL, and should be **bolded** and right justified (e.g., “Revised: 8/2015”).

*Comment: MM/YYYY proposed since approval date is not known.*
Selected Requirements of Prescribing Information

Contents: Table of Contents (TOC)

See Appendix for a sample tool illustrating Table of Contents format.

Yes 24. The TOC should be in a two-column format.

Comment:

Yes 25. The following heading must appear at the beginning of the TOC: “FULL PRESCRIBING INFORMATION: CONTENTS.” This heading should be in all UPPER CASE letters and bolded.

Comment:

Yes 26. The same title for the BW that appears in HL and the FPI must also appear at the beginning of the TOC in UPPER CASE letters and bolded.

Comment:

Yes 27. In the TOC, all section headings must be bolded and should be in UPPER CASE.

Comment:

Yes 28. In the TOC, all subsection headings must be indented and not bolded. The headings should be in title case [first letter of all words are capitalized except first letter of prepositions (for, of, to) and articles (a, an, the), or conjunctions (or, and)].

Comment:

Yes 29. The section and subsection headings in the TOC must match the section and subsection headings in the FPI.

Comment:

Yes 30. If a section or subsection required by regulation [21 CFR 201.56(d)(1)] is omitted from the FPI, the numbering in the TOC must not change. The heading “FULL PRESCRIBING INFORMATION: CONTENTS*” must be followed by an asterisk and the following statement must appear at the end of the TOC: “*Sections or subsections omitted from the full prescribing information are not listed.”

Comment:
**Selected Requirements of Prescribing Information**

**Full Prescribing Information (FPI)**

**FULL PRESCRIBING INFORMATION: GENERAL FORMAT**

1. The **bolded** section and subsection headings in the FPI must be named and numbered in accordance with 21 CFR 201.56(d)(1) as noted below. (Section and subsection headings should be in **UPPER CASE** and **title case**, respectively.) If a section/subsection required by regulation is omitted, the numbering must not change. Additional subsection headings (i.e., those not named by regulation) must also be **bolded** and numbered.

<table>
<thead>
<tr>
<th>BOXED WARNING</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 INDICATIONS AND USAGE</td>
</tr>
<tr>
<td>2 DOSAGE AND ADMINISTRATION</td>
</tr>
<tr>
<td>3 DOSAGE FORMS AND STRENGTHS</td>
</tr>
<tr>
<td>4 CONTRAINDICATIONS</td>
</tr>
<tr>
<td>5 WARNINGS AND PRECAUTIONS</td>
</tr>
<tr>
<td>6 ADVERSE REACTIONS</td>
</tr>
<tr>
<td>7 DRUG INTERACTIONS</td>
</tr>
<tr>
<td>8 USE IN SPECIFIC POPULATIONS</td>
</tr>
<tr>
<td>8.1 Pregnancy</td>
</tr>
<tr>
<td>8.2 Lactation (if not required to be in Pregnancy and Lactation Labeling Rule (PLLR) format, use “Labor and Delivery”)</td>
</tr>
<tr>
<td>8.3 Females and Males of Reproductive Potential (if not required to be in PLLR format, use “Nursing Mothers”)</td>
</tr>
<tr>
<td>8.4 Pediatric Use</td>
</tr>
<tr>
<td>8.5 Geriatric Use</td>
</tr>
<tr>
<td>9 DRUG ABUSE AND DEPENDENCE</td>
</tr>
<tr>
<td>9.1 Controlled Substance</td>
</tr>
<tr>
<td>9.2 Abuse</td>
</tr>
<tr>
<td>9.3 Dependence</td>
</tr>
<tr>
<td>10 OVERDOSAGE</td>
</tr>
<tr>
<td>11 DESCRIPTION</td>
</tr>
<tr>
<td>12 CLINICAL PHARMACOLOGY</td>
</tr>
<tr>
<td>12.1 Mechanism of Action</td>
</tr>
<tr>
<td>12.2 Pharmacodynamics</td>
</tr>
<tr>
<td>12.3 Pharmacokinetics</td>
</tr>
<tr>
<td>12.4 Microbiology (by guidance)</td>
</tr>
<tr>
<td>12.5 Pharmacogenomics (by guidance)</td>
</tr>
<tr>
<td>13 NONCLINICAL TOXICOLOGY</td>
</tr>
<tr>
<td>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</td>
</tr>
<tr>
<td>13.2 Animal Toxicology and/or Pharmacology</td>
</tr>
<tr>
<td>14 CLINICAL STUDIES</td>
</tr>
<tr>
<td>15 REFERENCES</td>
</tr>
<tr>
<td>16 HOW SUPPLIED/STORAGE AND HANDLING</td>
</tr>
<tr>
<td>17 PATIENT COUNSELING INFORMATION</td>
</tr>
</tbody>
</table>

**Comment:**

32. The preferred presentation for cross-references in the FPI is the section (not subsection) heading followed by the numerical identifier. The entire cross-reference should be in **italics** and enclosed within brackets. For example, “[see Warnings and Precautions (5.2)].”

**Comment:**

YES
33. For each RMC listed in HL, the corresponding new or modified text in the FPI must be marked with a vertical line on the left edge.

Comment: Original NDA submission, no RMC is applicable.

FULL PRESCRIBING INFORMATION DETAILS

FPI Heading

YES 34. The following heading “FULL PRESCRIBING INFORMATION” must be **bolded**, must appear at the beginning of the FPI, and should be in **UPPER CASE**.

Comment:

BOXED WARNING Section in the FPI

YES 35. All text in the BW should be **bolded**.

Comment:

YES 36. The BW must have a title in **UPPER CASE**, following the word “**WARNING**” and other words to identify the subject of the warning. (Even if there is more than one warning, the term, “**WARNING**” and not “**WARNINGS**” should be used.) For example: “**WARNING: SERIOUS INFECTIONS and ACUTE HEPATIC FAILURE**”. If there is more than one warning in the BW title, the word “and” in lower case can separate the warnings.

Comment:

CONTRAINDICATIONS Section in the FPI

YES 37. If no Contraindications are known, this section must state “None.”

Comment:

ADVERSE REACTIONS Section in the FPI

YES 38. When clinical trials adverse reactions data are included (typically in the “Clinical Trials Experience” subsection), the following verbatim statement (or **appropriate modification**) should precede the presentation of adverse reactions from clinical trials:

“No adverse reactions have been identified during post-approval use of (insert drug name). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

Comment:

N/A 39. When postmarketing adverse reaction data are included (typically in the “Postmarketing Experience” subsection), the following verbatim statement (or **appropriate modification**) should precede the presentation of adverse reactions:

“The following adverse reactions have been identified during post-approval use of (insert drug name). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.”

Comment: Original NDA submission - No post marketing Adverse reactions.
Selected Requirements of Prescribing Information

PATIENT COUNSELING INFORMATION Section in the FPI

**40.** Must reference any FDA-approved patient labeling in Section 17 (PATIENT COUNSELING INFORMATION). The reference statement should appear at the beginning of Section 17 and include the type(s) of FDA-approved patient labeling (e.g., Patient Information, Instructions for Use, or Medication Guide). Recommended language for the reference statement should include one of the following five verbatim statements that is most applicable:

- Advise the patient to read the FDA-approved patient labeling (Patient Information).
- Advise the patient to read the FDA-approved patient labeling (Instructions for Use).
- Advise the patient to read the FDA-approved patient labeling (Patient Information and Instructions for Use).
- Advise the patient to read the FDA-approved patient labeling (Medication Guide).
- Advise the patient to read the FDA-approved patient labeling (Medication Guide and Instructions for Use).

*Comment:* "Advise the patient to read the FDA-approved patient labeling" proposed.

**41.** FDA-approved patient labeling (e.g., Patient Information, Instructions for Use, or Medication Guide) must not be included as a subsection under Section 17 (PATIENT COUNSELING INFORMATION). All FDA-approved patient labeling must appear at the end of the PI upon approval.

*Comment:*
Selected Requirements of Prescribing Information

Appendix: Highlights and Table of Contents Format

HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use PROPRIETARY NAME safely and effectively. See full prescribing information for PROPRIETARY NAME.

PROPRIETARY NAME (non-proprietary name) dosage form, route of administration, controlled substance symbol
Initial U.S. Approval: YYYY

WARNING: TITLE OF WARNING
See full prescribing information for complete boxed warning.

• Text (4)
• Text (5.x)

RECENT MAJOR CHANGES
Section Title, Subsection Title (x.x) M/201Y
Section Title, Subsection Title (x.x) M/201Y

INDICATIONS AND USAGE
PROPRIETARY NAME is a (insert FDA established pharmacologic class text phrase) indicated for ... (1)

Limitations of Use: Text (1)

DOSAGE AND ADMINISTRATION
• Text (2.x)
• Text (2.x)

DOSAGE FORMS AND STRENGTHS
Dosage form(s): strength(s) (3)

CONTRAINDICATIONS
• Text (4)
• Text (4)

WARNINGS AND PRECAUTIONS
• Text (5.x)
• Text (5.x)

ADVERSE REACTIONS
Most common adverse reactions (incidence > x%) are text (6.x)

To report SUSPECTED ADVERSE REACTIONS, contact name of manufacturer at toll-free phone # or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS
• Text (7.x)
• Text (7.x)

USE IN SPECIFIC POPULATIONS
• Text (8.x)
• Text (8.x)

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling OR and Medication Guide.

Revised: M/201Y

FULL PRESCRIBING INFORMATION: CONTENTS*

1 WARNING: TITLE OF WARNING
9 DRUG ABUSE AND DEPENDENCE
9.1 Controlled Substance
9.2 Abuse
9.3 Dependence

2 INDICATIONS AND USAGE
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
12.4 Microbiology
12.5 Pharmaco genomics

3 DOSAGE AND ADMINISTRATION
13 NONCLINICAL TOXICOLOGY
13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility
13.2 Animal Toxicology and/or Pharmacology

4 CONTRAINDICATIONS
14 CLINICAL STUDIES
14.1 Subsection Title
14.2 Subsection Title

5 WARNINGS AND PRECAUTIONS
15 REFERENCES

6 ADVERSE REACTIONS
16 HOW SUPPLIED/STORAGE AND HANDLING
6.1 Clinical Trials Experience
6.2 Immunogenicity
6.3 Postmarketing Experience

7 DRUG INTERACTIONS
17 PATIENT COUNSELING INFORMATION
7.1 Subsection Title

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy
8.2 Lactation (if not required to be in PLLR format use Labor and Delivery)
8.3 Females and Males of Reproductive Potential (if not required to be in PLLR format use Nursing Mothers)
8.4 Pediatric Use
8.5 Geriatric Use
8.6 Subpopulation X

* Sections or subsections omitted from the full prescribing information are not listed.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

----------------------------------------------------
MYUNG JOO P HONG
02/01/2016

ELIZABETH G THOMPSON
02/01/2016